NEW THERAPEUTIC PERSPECTIVES IN IRRITABLE BOWEL SYNDROME: TARGETING LOW-GRADE INFLAMMATION, IMMUNO-NEUROENDOCRINE AXIS, MOTILITY, SDECRETION AND BEYOND. by Sinagra, E. et al.
New therapeutic perspectives in irritable bowel syndrome: 
Targeting low-grade inflammation, immuno-neuroendocrine 
axis, motility, secretion and beyond
Emanuele Sinagra, Gaetano Cristian Morreale, Ghazaleh Mohammadian, Giorgio Fusco, Valentina Guarnotta, 
Giovanni Tomasello, Francesco Cappello, Francesca Rossi, Georgios Amvrosiadis, Dario Raimondo
Emanuele Sinagra, Francesca Rossi, Dario Raimondo, 
Gastroenterology and Endoscopy Unit, Fondazione Istituto 
Giuseppe Giglio, Contrada Pietra Pollastra Pisciotto, 90015 
Cefalù, Italy
Emanuele Sinagra, Giovanni Tomasello, Francesco 
Cappello, Euro-Mediterranean Institute of Science and 
Technology, 90100 Palermo, Italy 
Emanuele Sinagra, Giovanni Tomasello, Francesco 
Cappello, Department of Experimental Biomedicine and 
Clinical Neuroscience, Section of Human Anatomy, University of 
Palermo, 90100 Palermo, Italy
Gaetano Cristian Morreale, Georgios Amvrosiadis, Unit 
of Gastroenterology, Ospedali Riuniti Villa Sofia-Vincenzo 
Cervello, 90100 Palermo, Italy
Ghazaleh Mohammadian, Department of Medicine, Division 
of Gastroenterology and Hepatology, Karolinska Institutet, 
Karolinska University Hospital, Huddinge, 17176 Stockholm, 
Sweden
Giorgio Fusco, Unit of Internal Medicine, Ospedali Riuniti Villa 
Sofia-Vincenzo Cervello, 90100 Palermo, Italy
Valentina Guarnotta, Section of Cardio-Respiratory and 
Endocrine-Metabolic Diseases, Biomedical Department of 
Internal and Specialist Medicine, University of Palermo, Palermo 
90127, Italy
Author contributions: Sinagra E designed the study; Sinagra E, 
Mohammadian G, Amvrosiadis G, Rossi F, Morreale GC wrote 
the paper; Guarnotta V, Cappello F and Fusco G contributed to 
the revision of the manuscript; Tomasello G and Raimondo D 
supervised the work.
Conflict-of-interest statement: All the authors declare that this 
research received no specific grant from any funding agency in 
the public, commercial, or not-for-profit sectors, thus disclosing 
any conflict of interests regarding such work.
Open-Access: This article is an open-access article which was 
selected by an in-house editor and fully peer-reviewed by external 
reviewers. It is distributed in accordance with the Creative 
Commons Attribution Non Commercial (CC BY-NC 4.0) license, 
which permits others to distribute, remix, adapt, build upon this 
work non-commercially, and license their derivative works on 
different terms, provided the original work is properly cited and 
the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
Manuscript source: Invited manuscript
Correspondence to: Dr. Emanuele Sinagra, Gastroenterology 
and Endoscopy Unit, Fondazione Istituto Giuseppe Giglio, 
Contrada Pietra Pollastra Pisciotto, snc, 90015 Cefalù, 
Italy. emanuelesinagra83@googlemail.com
Telephone: +39-92-1920712
Fax: +39-92-1920406
Received: February 2, 2017
Peer-review started: February 8, 2017
First decision: March 16, 2017
Revised: April 15, 2017
Accepted: July 4, 2017  
Article in press: July 4, 2017
Published online: September 28, 2017
Abstract
Irritable bowel syndrome (IBS) is a chronic, recurring, 
and remitting functional disorder of the gastrointestinal 
tract characterized by abdominal pain, distention, and 
changes in bowel habits. Although there are several 
drugs for IBS, effective and approved treatments for 
one or more of the symptoms for various IBS subtypes 
are needed. Improved understanding of pathophy-
siological mechanisms such as the role of impaired bile 
acid metabolism, neurohormonal regulation, immune 
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dysfunction, the epithelial barrier and the secretory 
properties of the gut has led to advancements in the 
treatment of IBS. With regards to therapies for restoring 
intestinal permeability, multiple studies with prebiotics 
and probiotics are ongoing, even if to date their efficacy 
has been limited. In parallel, much progress has been 
made in targeting low-grade inflammation, especially 
through the introduction of drugs such as mesalazine 
and rifaximin, even if a better knowledge of the 
mechanisms underlying the low-grade inflammation in 
IBS may allow the design of clinical trials that test the 
efficacy and safety of such drugs. This literature review 
aims to summarize the findings related to new and 
investigational therapeutic agents for IBS, most recently 
developed in preclinical as well as Phase 1 and Phase 2 
clinical studies.
Key words: Therapy; Low grade inflammation; Motility; 
Secretion; Irritable bowel syndrome; Immunoendocrine 
axis
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Irritable bowel syndrome (IBS) is a chronic, 
recurring, and remitting functional disorder of the 
gastrointestinal tract characterized by abdominal pain, 
distention, and changes in bowel habits. Despite there 
are several drugs for IBS, effective and approved 
treatments for one or more of the symptoms for 
various IBS subtypes are needed. The understanding 
of pathophysiological mechanisms such as the role 
of impaired bile acid metabolism, neurohormonal 
regulation, immune dysfunction, the epithelial barrier and 
secretory properties of the gut has led to advancements 
in the treatment of IBS. This literature review aims to 
summarize the findings relating the new and investi-
gational therapeutic agents for IBS, most recently 
developed in preclinical as well as Phase 1 and Phase 2 
clinical studies.
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INTRODUCTION
Irritable bowel syndrome (IBS) is a chronic, recurring, 
and remitting functional disorder of the gastrointestinal 
(GI) tract characterized by abdominal pain, distention, 
and changes in bowel habits that do not have a known 
structural or anatomical explanation[1].
IBS is a global problem, with anywhere from 5% to 
15% of the general population showing symptoms that 
would satisfy a definition of IBS[2-4]. IBS considerably 
affects quality of life and imposes a profound burden 
on patients, physicians and the health-care system[5]. 
For example, the IBIS-C study recently assessed the 
socio-economic burden of moderate-to-severe IBS with 
constipation in six European countries (France, Germany, 
Italy, Spain, Sweden and the United Kingdom), showing 
that IBS represents a main cause of absenteeism in the 
workplace[6].
Regarding the sex-related prevalence of IBS, in 
Western countries, the prevalence of IBS in women 
outnumbers that in men by 2:1[7,8], and within the 
patient population who have consultations with primary 
care physicians, women outnumber men by 3:1[7,9]. 
Finally, in tertiary care settings, the number of women 
with IBS is 4 to 5 times higher than the number of 
men[7-10].
According to Rome Ⅲ, IBS is defined based on the 
presence of: recurrent abdominal pain or discomfort 
at least 3 d/mo in the past 3 mo associated with two 
or more of the following: (1) improvement with defeca-
tion; (2) onset associated with a change in frequency of 
stool; and (3) onset associated with a change in form 
(appearance) of stool. 
These criteria should be fulfilled for the past 3 mo 
with symptom onset at least 6 mo before diagnosis[11]. 
Recently, the Rome Ⅳ criteria implemented the know-
ledge accumulated since Rome Ⅲ was published almost 
ten years ago.
According to Rome Ⅳ, IBS is defined on the basis 
of the presence of: Recurrent abdominal pain, on 
average, at least 1 d per week in the last 3 mo, asso-
ciated with 2 or more of the following criteria: (1) 
related to defecation; (2) associated with a change in 
frequency of stool; and (3) associated with a change 
in form (appearance) of stool. These criteria should be 
fulfilled for the last 3 mo with symptom onset at least 6 
mo before diagnosis[12].
In contrast to the Rome Ⅲ criteria, the term dis-
comfort has been deleted from the last definition and 
from subsequent diagnostic criteria because not all 
languages have the term “discomfort”. This word has 
different meanings in different languages, which can 
result in ambiguity with patients[12]. Furthermore, 
the last definition implies a change in the frequency 
of abdominal pain, highlighting that patients should 
have symptoms of abdominal pain at least 1 d per 
week during the past 3 mo[12]. Finally, the sentence 
“improvement with defecation” was substituted in the 
current definition by “related to defecation”, as a large 
subset of IBS patients do not have an improvement in 
abdominal pain with defecation but instead complain of 
worsening[12]. 
According to the Rome Ⅳ criteria, IBS is subtyped 
according to the predominant bowel habit as follows: 
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IBS with constipation (IBS-C), IBS with diarrhoea 
(IBS-D), mixed type (IBS-M), and unclassified (IBS-U)[12]. 
The definition of bowel habit type is based on the 
patient’s description of the stool form by referring to 
the Bristol Stool Scale[13]. Furthermore, IBS patients 
can be grouped into sporadic (nonspecific) and post-
infectious (PI-IBS)/inflammatory bowel disease (IBD)-
associated (IBD-IBS)[14,15].
Although there are several drugs for IBS in the 
pipeline, there is a continuous need for effective and 
approved treatments for one or more of the symptoms 
of IBS subtypes[16-18]. The understanding of pathophy-
siological mechanisms such as the role of altered bile 
acid metabolism, neurohormonal regulation, immune 
dysfunction, the epithelial barrier and secretory pro-
perties of the gut has led to progress in the treatment 
options of IBS (Figure 1)[18,19].
This literature review aims to summarize the 
findings relating the new and investigational therapeutic 
agents for IBS most recently developed in preclinical as 
well as Phase 1 and Phase 2 clinical studies.
MATERIALS AND METHODS
We carried out a bibliographic search in MEDLINE 
for the period January 1966 to December 2016 and 
focused on identifying publications describing the 
new therapeutic pharmacological approaches in 
IBS. Information was also obtained from abstracts 
and the latest results found in the Clinicaltrial.gov 
database. The keywords used were: irritable bowel 
syndrome, inflammation, immunoendocrine axis, 
intestinal permeability, IBS-C, IBS-D, therapy. The 
inclusion criteria to select articles were based on design 
(systematic reviews, meta-analysis, clinical trials, and 
experimental studies on animals) and population (adult 
patients > 18 years of age). We excluded articles not 
relevant for this topic.
According to the abovementioned criteria, 5127 
studies were found and 4810 studies were excluded 
because they were not relevant for this topic (Figure 2).
LOW-GRADE INFLAMMATION IN 
IRRITABLE BOWEL SYNDROME
Recently, the scientific community has focused its 
attention on the pivotal role of low-grade mucosal 
inflammation in IBS, considering evidence showing 
that some patients with IBS have an increased number 
of inflammatory cells in the colonic and ileal mucosa, 
with regard to control patients[20]. 
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Figure 2  Literature findings on the relationship between irritable bowel 
syndrome and inflammation (n = 317). RCT: Randomized controlled trials.
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Figure 1  Complex interplay between low-grade inflammation, immuno-neuroendocrine axis, and microbiota. Brain (influenced by multiple innate and acquired 
factors) and gut interact bidirectionally to shape the clinical phenotype of irritable bowel syndrome (IBS). This bi-directional pathway acts not only on gastrointestinal 
motility, visceral sensitivity and secretion; however, the influence of both the immune system and microbiota modulates several functions that could create the 
definitive clinical phenotype of IBS.
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day for 14 d as well as in patients experiencing a 
recurrence of symptoms.
Rifaximin improves IBS symptoms through a variety 
of mechanisms directed at the gastrointestinal tract. In 
fact, much evidence from animal experiments shows 
that rifaximin either improves or maintains microbiota 
diversity and bacterial composition in IBS, reduces 
intestinal cytokine inflammation, provides gut-barrier 
protection preventing attachment and internalization 
of coliforms and pathogens with reduced epithelial cell 
inflammation and pathogen-induced inflammatory 
response, and reduces visceral hyperalgesia[28]. 
In a combined analysis of two separate Phase 3 
trials (TARGET 1 and 2), a 14-d course of rifaximin 550 
mg three times daily in IBS-D patients significantly 
increased the percentage of relief of global IBS symptoms 
and improved IBS-related distention and abdominal pain, 
discomfort, and loose or watery stools compared with 
placebo for up to 10 wk post-treatment[29,30]. 
Successively, TARGET 3 was performed to test 
the safety and efficacy of a repeated treatment with 
rifaximin in patients experiencing a recurrence of IBS 
symptoms. In this study, the percentage of responders 
during the 18-wk follow-up (in terms of pain and stool 
consistency improvements) to randomized repeat 
treatment was significantly greater with rifaximin vs 
placebo[31]. The safety profile of rifaximin in patients 
with IBS-D was generally similar to that observed with 
placebo[30].
In fact, constipation was only reported in 1 (0.3%) 
patient in the rifaximin group and 3 (1.0%) patients in 
the placebo group. Only one patient in each treatment 
group suspended the drug. One case of Clostridium 
difficile infection occurred (in a patient who had been 
off of rifaximin for several weeks but was receiving a 
concomitant systemic antibiotic)[30,31]. 
In conclusion, these trials show that a 2-wk course 
of rifaximin could improve IBS-D-related symptoms, 
and in the case of persistence of symptoms, retreat-
ment may ameliorate abdominal pain and stool 
consistency with possible improvements in bloating 
and stool urgency in some patients. While patients 
were retreated within an 18-wk period of follow-up in 
the study, it is still unclear as to when and how often 
treatment should be given. In addition, the identification 
of those patients who might likely respond to rifaximin 
remains to be investigated. 
Recently, Ghoshal et al[32] evaluated symptom 
resolution among IBS patients with or without small 
intestinal bacterial overgrowth (SIBO) on norfloxacin 
treatment and its efficacy in obtaining negative SIBO 
test results as compared with placebo. In this study, 
80 IBS patients (Rome Ⅲ) were evaluated for SIBO 
by gut aspirate culture. Patients with a colony count ≥ 
10 CFU/mL and those without SIBO were separately 
randomized to 800 mg/d norfloxacin for 10 d or 
placebo. The global symptom score (blind), Rome Ⅲ 
In fact, the intestinal mucosa harbours a florid 
immune system that can be regarded as “physiologically 
inflamed”[20,21]. Thus, low-grade inflammation, which 
likely plays a multifactorial role in IBS pathophysiology, 
can only be evaluated using quantitative assess-
ments[20-22].
The available data[23,24] on low-grade inflammation 
in IBS patients is often expressed as average numbers 
and are mainly focused on IBS-D. Thus, it is unclear 
whether this event occurs only in selected subsets of 
IBS patients[25].
Therefore, IBS could be considered a micro-organic 
disease, where there is an increased number of 
mucosal immunocytes (i.e., mast cells, eosinophils, 
and T cells) in adult and paediatric patients. Several 
precipitating factors have been claimed, including food 
allergy, abnormal microbiota, bile acid malabsorption, 
and increased intestinal permeability[26]. The magnitude 
of the inflammatory response is several-fold less 
than that seen in acute inflammation in inflammatory 
bowel disease. The above-reported evidence provides 
a rationale to evaluate the efficacy of intestinal anti-
inflammatory therapies in patients with IBS that we will 
touch upon in the next section.
ANTI-INFLAMMATORY THERAPIES IN 
IRRITABLE BOWEL SYNDROME
Corticosteroids
In the study performed by Dunlop et al[24], twenty-nine 
patients with post-infectious irritable bowel syndrome 
underwent a randomized, double-blind, placebo-
controlled trial of 3 wk of oral prednisolone, 30 mg/d. 
Mucosal enterochromaffin cells, T lymphocytes and 
mast cells were evaluated in rectal biopsies before and 
after treatment, and bowel symptoms were reported in 
a daily diary. In this study, enterochromaffin cell counts 
did not change significantly after either prednisolone or 
placebo. Although lamina propria T-lymphocyte counts 
decreased significantly after prednisolone, but not 
after placebo, this was not linked with any significant 
treatment-related improvement in abdominal pain, 
diarrhoea, frequency or urgency[24].
Antibiotics
Rifaximin is a rifamycin derivative that acts by in-
hibiting bacterial ribonucleic acid (RNA) synthesis. It 
is virtually unabsorbed after oral administration, so it 
is used mainly to treat local dysfunctions within the 
gastrointestinal tract[27]. 
The Food and Drug Administration (FDA) initially 
approved rifaximin to treat traveller’s diarrhoea caused 
by Escherichia coli and to prevent the recurrence of 
hepatic encephalopathy.
Successively, the FDA approved rifaximin in IBS-D 
“naive” patients at a dose of 550 mg three times a 
Sinagra E et al . New therapeutic perspectives in IBS
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criteria, aspirate culture, and glucose hydrogen breath 
test were assessed before and 1 mo after treatment, 
and patients were followed up for 6 mo. Although 
norfloxacin was more effective at decreasing the 
symptom score at 1 mo among patients with compared 
with those without SIBO but not placebo, the scores 
were comparable at 6 mo. Symptoms more often 
resolved to turn Rome Ⅲ negative in SIBO patients 
treated with norfloxacin compared with placebo at 1 
mo. Patients without SIBO and a colony count of 10 
CFU/mL responded more than those with a colony 
count less than 10 CFU/mL[32].
Mast cell stabilizers
Since mast cell activation was thought to be involved 
in visceral hypersensitivity, a study was undertaken by 
Klooker et al[33] to evaluate the effect of ketotifen, a 
mast cell stabilizer, on rectal sensitivity and symptoms 
in patients with IBS. In this case-control study, 60 
patients with IBS underwent a barostat study to assess 
rectal sensitivity before and after 8 wk of treatment. 
After the initial barostat, patients were randomised 
to receive ketotifen or placebo. Ketotifen increased 
the threshold for discomfort in patients with IBS and 
visceral hypersensitivity but not placebo. This effect 
was not observed in normosensitive patients with 
IBS. Ketotifen significantly reduced abdominal pain 
and other IBS symptoms and improved quality of life. 
However, whether this effect was secondary to the mast 
cell stabilising properties of ketotifen or H1 receptor 
antagonism remains a topic of future research[33]. 
Successively, Lobo et al[34] showed a clinical Benefit 
of Disodium Cromoglycate (DSCG) in IBS in a double-
blind, placebo-controlled clinical assay with prolonged 
(6 mo) oral administration of DSCG (DSCG), since it 
induces mast cell-mediated recovery of the healthy-
like innate immunity gene expression profile in the 
jejunal mucosa[34].
Finally, since histamine sensitizes the nociceptor 
transient reporter potential channel V1 (TRPV1) and has 
been observed to play role in visceral hypersensitivity 
in animals, Wouters et al[35,36] investigated the role 
of ebastine, an antagonist of histamine receptor H1 
(HRH1), in reducing symptoms of patients in a rando-
mized placebo-controlled trial. After a 2-wk run-in 
period, subjects were enrolled randomly to groups 
given either the HRH1 antagonist ebastine or placebo 
for 12 wk. Rectal biopsy specimens were collected, 
barostat studies were performed, and symptoms 
were recorded (using the validated gastrointestinal 
symptom rating scale) before and after the 12-wk 
period. Patients were followed up for a further 2 wk. 
The primary end point of the study was the evaluation 
of ebastine efficacy on the symptom score evoked by 
rectal distension. Compared with the placebo group, 
patients treated with ebastine had reduced visceral 
hypersensitivity, increased symptom relief, and reduced 
abdominal pain scores[35,36].
Mesalazine
The therapeutic potential of aminosalicylates, whose 
benefits in chronic inflammatory bowel diseases are 
well known, has been focused on as a potential cure 
for IBS[37,38]. 
The largest studies on mesalazine in IBS have 
been conducted by Barbara and Lam. Barbara et al[39] 
conducted a phase 3, multicentre, tertiary setting, 
randomised, double-blind placebo-controlled trial in 
patients with Rome Ⅲ-confirmed IBS. Patients were 
randomly assigned to either 800 mg mesalazine or 
placebo three times daily for 12 wk and were followed 
for an additional 12 wk. The primary efficacy endpoint 
was satisfactory relief of abdominal pain/discomfort for 
at least half of the weeks of the treatment period. The 
secondary endpoint was satisfactory relief of overall 
IBS symptoms. The responder patients were 68.6% in 
the mesalazine group vs 67.4% in the placebo group. 
However, with the 75% rule or > 75% rule, there was 
a higher percentage of responders in the mesalazine 
group than placebo of 11.6% and 5.9%, respectively, 
although these differences were not significant. For 
the key secondary endpoint, in the mesalazine group, 
overall symptom improvement was observed and a 
significant difference of 15.1% vs placebo with the > 
75% rule was reached. The authors concluded that 
mesalazine treatment was not superior to placebo on 
the study primary endpoint, but a subgroup of patients 
with IBS had a sustained therapy response and benefits 
from mesalazine therapy[39].
On the other hand, Lam et al[40] conducted a 
double-blind, randomised placebo-controlled trial of 2 g 
mesalazine twice daily compared with placebo for 3 mo 
in Rome Ⅲ criteria patients with IBS-D. The authors 
compared the mesalazine and placebo effects on stool 
frequency as the primary endpoint and secondarily 
assessed the effect of mesalazine on abdominal pain, 
stool consistency, urgency and satisfactory relief of IBS 
symptoms. In total, 136 IBS-D patients (82 female, 54 
male) were enrolled; 10 patients withdrew from each 
group. The intention to treat analysis showed that 
the mean daily stool frequency during weeks 11 and 
12 was 2.8 (SD 1.2) in the mesalazine group and 2.7 
(SD 1.9) in the placebo group, with a group difference 
of 0.1. The authors concluded that mesalazine did 
not ameliorate abdominal pain, stool consistency or 
percentage with satisfactory relief compared with 
placebo during the last 2 weeks’ follow-up. However 
a post hoc analysis in 13 post-infectious patients with 
IBS tended to show benefit, even though this finding 
needs to be confirmed in larger studies[40].
A point of weakness of these studies is that the 
use of endpoints for response may be easily met 
by patients in the placebo arm, resulting in placebo 
response rates of almost 70% for satisfactory relief 
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of abdominal pain or discomfort and > 60% for 
satisfactory relief of overall IBS symptoms in the 
trial performed by Barbara et al[39] and in > 40% 
for satisfactory relief of IBS symptoms in the trial 
performed by Min et al[41].
It may have therefore have been preferable to use 
a once daily dosing schedule in both trials in order to 
reduce the placebo response rates, thus increasing 
the likelihood of detecting a statistically significant 
difference between mesalazine and placebo.
Based on this evidence, it is necessary that further 
studies prove the efficacy of mesalazine for IBS. 
Studies aimed at evaluating the role of aminosali-
cylates and other potential anti-inflammatory treatment 
options, including probiotics, non-absorbable anti-
biotics, histamine receptor antagonists and protease 
inhibitors on IBS symptoms or pathophysiology are now 
warranted[39].
Table 1 sums up the literature findings about anti-
inflammatory therapies in irritable bowel syndrome.
INTESTINAL PERMEABILITY IN IRRITABLE 
BOWEL SYNDROME
An increase in intestinal permeability can be seen in 
Drug Ref. No. of patients Study design Outcome
Corticosteroids 
(prednisolone)
Dunlop et al[24] 29 patients with post-
infectious irritable bowel 
syndrome 
Randomized, double-blind, placebo-
controlled trial of 3 wk of oral 
prednisolone, 30 mg/d
Not associated with any significant 
treatment-related improvement in abdominal 
pain, diarrhoea, frequency or urgency 
Antibiotics 
(Rifaximin)
Pimentel et al[29] 623 IBS patients in TARGET 
1 and 637 IBS in TARGET 2
Phase 3 trials, 14 d with rifaximin 550 
mg 3 times daily
Significantly increased the percentage of 
relief of global IBS symptoms and improved 
IBS-related bloating and abdominal pain, 
discomfort, and loose or watery stools, with 
regard to placebo for up to 10 wk post-
treatment 
Target 1 e 2
Antibiotics 
(norfloxacin)
Ghoshal et al[32] 80 IBS patients evaluate for 
SIBO
Randomized, double-blind, placebo-
controlled trial; patients were 
randomized to 800 mg/d norfloxacin 
for 10 d or placebo
Although norfloxacin was more effective at 
reducing the symptom score at 1 mo among 
patients with compared with those without 
SIBO but not placebo, the scores were 
comparable at 6 mo. Symptoms more often 
resolved to turn Rome Ⅲ negative in SIBO 
patients treated with norfloxacin compared 
with placebo at 1 mo
Mast cell stabilizers 
(Ketotifen)
Klooker et al[33] 60 IBS patiens  Case Control study; abarostat study to 
assess rectal sensitivity before and after 
8 wk of treatment and, after the initial 
barostat, patients were randomised to 
receive ketotifen or placebo
Ketotifen but not placebo increased the 
threshold for discomfort in patients with IBS 
with visceral hypersensitivity, but this effect 
was not observed in normosensitive patients 
with IBS. Ketotifen significantly decreased 
abdominal pain and other IBS symptoms and 
improved quality of life
Mast cells stabilizers 
(DSCG)
Lobo et al[34] Randomized, double-blind, placebo-
controlled trial; with prolonged (6 mo) 
oral administration of DSCG
Induces Mast Cell-Mediated Recovery 
of Healthy-Like Innate Immunity Genes 
Expression Profile in the Jejunal Mucosa
Mast cells stabilizers 
(ebastin)
Wouters et al[35] 65 IBS patients Double-blind placebo-controlled trial,  
after 2-wk run-in period, subjects were 
assigned randomly to groups ebastine  
(20 mg/d; n = 28) or placebo (n = 27) 
for 12 wk
Compared with subjects given placebo, 
those given ebastine had reduced visceral 
hypersensitivity, increased symptom relief, 
and reduced abdominal pain scores
Mesalazine Barbara et al[39] 185 patients with IBS A phase 3, multicentre, tertiary 
setting, randomised, double-blind, 
placebo-controlled trial in patients 
with Rome Ⅲ confirmed IBS. Patients 
were randomly assigned to either 
mesalazine, 800 mg, or placebo, 
three times daily for 12 wk, and were 
followed for additional 12 wk
Mesalazine treatment was not superior than 
placebo on the study primary endpoint, but 
a subgroup of patients with IBS showed a 
sustained therapy response and benefits from 
a mesalazine therapy
Lam et al[40] 136 patients with IBS-D A double-blind, randomised placebo-
controlled trial of 2 g mesalazine twice 
daily compared with placebo for 3 mo 
The authors concluded that mesalazine 
did not improve abdominal pain, stool 
consistency or percentage with satisfactory 
relief compared with placebo during the 
last 2 weeks’ follow-up, however a post hoc 
analysis in 13 post-infectious patients with 
IBS appeared to show benefit but this needs 
confirmation in a larger group[40]
Table 1  Summary of the literature findings about anti-inflammatory therapies in irritable bowel syndrome
IBS : Irritable bowel syndrome.
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many conditions, such as infectious gastroenteritis and 
irritable bowel disease[42]. The intestinal barrier has 
long been a focus of gastroenterological research[43] 
and its role in IBS has been discussed in many 
studies. Most studies show an increase in intestinal 
permeability of patients with IBS-D and post-infectious 
IBS (PI-IBS)[43-46].
Among the first to describe intestinal permeability 
in patients with PI-IBS were Spiller et al[47], who 
detected an increased lactulose/mannitol ratio in the 
urine of IBS patients compared to healthy controls. 
Marshall et al[48] also described an increase in 
permeability of patients with IBS after an outbreak of 
bacterial gastroenteritis but could not show a difference 
in permeability between PI-IBS and non PI-IBS. 
There are genetic risk factors for developing PI-
IBS and CDH1, which codes for E-cadherin, a tight 
junction (TJ) protein that is involved in the epithelial 
barrier function of the gut[49], hence suggesting the 
pathophysiological mechanism through which some 
patients experience increased permeability. 
The mechanism of increased permeability in patients 
with IBS is suggested to involve tight junction dys-
function or involvement of the adherence proteins[44]. 
Among factors that could influence permeability is 
stress. Male soldiers were evaluated in a prospective 
study during and after combat training with an increase 
in physiological and psychological stress. Their training 
induced an increase in gastrointestinal symptoms and 
alteration in the permeability of the gut barrier[50]. 
Since stress has been suggested to be one of the 
pathophysiological factors involved in developing 
IBS, this mechanism could explain the reason for the 
gastrointestinal symptoms[51].
Another factor that has been evaluated is the 
intraluminal content of patients with IBS, where faecal 
supernatants from patients have increased the colonic 
permeability in mice[52,53].
Both intracellular [zonula occludens (ZO)-1, ZO-2, 
and ZO-3, and cingulin] and surface-membrane 
proteins [occludin, claudins, and junctional adhesion 
molecules (JAM)] are the main components of TJ[26,54].
 
Adherens junctions are mainly made up of e-cadherin, 
catenin, and actin filaments[26,55].
Inflammation has also been described to be a 
factor in increasing intestinal permeability, not only in 
inflammatory bowel disease[43] but also in IBS, where 
the increase in mast cells and the mediators increased 
the effects on the intercellular junctions[44].
Finally, other factors, such as hormonal and neuro-
hormonal pathways, nutritional factors, ethanol con-
sumption and several drugs (nonsteroidal anti-inflam-
matory drugs, methotrexate, tacrolimus, protonic pump 
inhibitors), could affect the intestinal barrier, a factor 
that needs to be further evaluated[26]. The knowledge 
of affection of the intestinal permeability in IBS patients 
will help in the development of new therapies in order 
to restore the gut barrier, a topic we will touch upon in 
the next section.
Table 2 sums up the literature findings about 
therapies restoring intestinal permeability in irritable 
bowel syndrome.
THERAPIES RESTORING INTESTINAL 
PERMEABILITY IN IRRITABLE BOWEL 
SYNDROME
Probiotics
The human intestinal microbiota represents one of 
the densest, biodiverse, and rapidly evolving bacterial 
ecosystems. The intestinal microbiome, that is, its 
collective genome, is an adaptive entity that varies 
with diet, lifestyle and environment, providing a further 
metabolic flexibility to the human super organism and 
functional traits that humans have not evolved on their 
own[56]. Therefore, the potential of manipulating the 
gut microbiota in these disorders is assessed[57].
The mechanisms through which probiotics alter the 
intestinal microbial flora could be direct, changing the 
bacterial macroenvironment of the lumen, or indirect, 
through the stimulation of the immune system and 
the improvement of mucosal function, for example, 
by modulating the invasion and adherence of the 
epithelial cells of the gut by pathogenic bacteria, thus 
normalizing gut permeability[58-60]. The use of probiotics 
in patients with IBS seems to be effective in achieving 
improvement in the global IBS symptoms[61,62], but how 
it affects the intestinal permeability is less evaluated in 
humans[46]. Most studies have shown that altering the 
intraluminal content affects the barrier functions of the 
gut, and studies on rodent models of IBS have shown 
different data[63].  
Despite the growing interest of the scientific co-
mmunity in research in the field of probiotics, the inter-
pretation of the scientific literature on the value of 
these preparations’ results is difficult due to the wide 
variability in the species, strains and doses employed 
in the preparations as well as the low methodological 
quality of the available trials, often due to the poor 
design and the small sample size.
Several meta-analysis have been published on 
this topic[64-66], all concluding that probiotics might be 
efficacious in IBS, but the actual benefit and the most 
effective species and strains are uncertain.
In the meta-analysis performed by Ford et al[61], 
including forty-three randomized controlled trials, 
probiotics showed beneficial effects on global IBS, 
abdominal pain, bloating, and flatulence scores[61]. 
Probiotics appeared to be successful in chronic idiopathic 
constipation (CIC), but there were only two randomized 
controlled trials, and again, since trials for probiotics 
are few in number, no specific conclusions could be 
obtained[61].
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In the last updated meta-analysis performed by 
Mazurak et al[67], including fifty-six papers (twenty-
seven studies using multi-species bacterial preparations 
and twenty-nine using single-strain probiotics), they 
analysed the efficacy of probiotics regarding patients 
included, treatment duration, probiotic dosage, and 
outcome measures. According to the authors, the 
heterogeneity of the studies of probiotics in IBS impairs 
the value of meta-analyses. The use of different 
bacterial strains and different mixtures of these strains, 
as well as different dosages, may be the main factors 
contributing to this heterogeneity[67]. Currently, there is 
limited evidence for the efficacy of a small number of 
single-strain probiotics in IBS (mostly bifidobacteria), 
and this evidence leads to the performance of trials 
with inclusion and exclusion criteria closely following 
the European Medicines Agency (EMA) and the Food 
and Drug Administration (FDA) guidelines for clinical 
trials in IBS[68,69], including the definition of minimal 
severity for inclusion, global primary endpoints, and 
adequate secondary end-points (pain, bloating, and a 
clinically meaningful responder definition). Such trials 
should include at least 8 wk of therapy, an adequate 
follow-up period and restriction to one of the different 
IBS subtypes[67].
Glutamine
Glutamine is one of the compounds that has been 
investigated as a treatment of conditions with leaky 
gut. It has been shown to regulate the protein turnover 
in enterocytes of pig[70], reduce intestinal permeability 
in intestinal cell cultures and maintain transepithelial 
resistance[71]. Glutamine has also been shown to 
maintain the integrity of the intestinal barrier in critically 
ill patients by reducing the incidence of infections[72]. 
Glutamine treatment in patients with Crohn’s disease 
was recently reviewed in a Cochrane analysis[73]. In this 
review, only two randomized controls were included, 
and neither showed a significant difference in the 
permeability and neither had any effect on clinical 
remission.
Glutamine treatment in patients with IBS is less 
examined. Glutamine synthetase expression is lower 
in the small bowel and colonic mucosa of patients 
with IBS-D with increased intestinal permeability[74]. 
Therefore, one recent pilot study on IBS-D showed 
that with a higher glutamine concentration, Claudin-1 
expression increases, thus improving the perme-
ability[75]. However, further studies are needed for using 
glutamine as a supplement treatment for IBS. 
Larazotide acetate
Larazotide acetate (LA) is a tight-junction regulator 
peptide preventing the opening of intestinal epithelial 
TJ[76]. The safety, tolerance and pharmacokinetics of 
LA were studied in a randomized double-blind placebo-
controlled study conducted on celiac disease subjects 
challenged with gluten[76,77]. 
Recently, in a multicentre, randomized, double-
blind placebo-controlled study, LA at doses of 0.5, 1, 
or 2 mg 3 times daily was evaluated to relieve ongoing 
symptoms in 342 adults with celiac disease who had 
been on a gluten-free diet (GFD) for 12 mo or longer 
and maintained their current GFD during the study. A 
0.5 mg dose of Larazotide acetate appeared to reduce 
signs and symptoms in celiac disease patients on a 
Drug Ref. No. of patients Study design Outcome
Probiotics Ford et al[61] Forty-three RCTs were 
eligible for inclusion
Metanalysis Probiotics had beneficial effects on global IBS, 
abdominal pain, bloating, and flatulence scores. Data 
for prebiotics and synbiotics in IBS were sparse. 
Probiotics appeared to have beneficial effects in CIC 
(mean increase in number of stools per week = 1.49; 
95%CI: 1.02-1.96), but there were only two RCTs. 
Synbiotics also appeared beneficial (RR of failure to 
respond to therapy = 0.78; 95%CI: 0.67-0.92). Again, 
trials for prebiotics were few in number, and no 
definite conclusions could be drawn
Mazurak et al[67] Fifty-six papers Metanalysis The heterogeneity of the studies of probiotics in IBS 
questions the value of meta-analyses and the use of 
different bacterial strains and different mixtures of 
these strains, as well as different dosages, are the main 
contributors to this heterogeneity
Glutamine Akobeng et al[73] Two randomized trial Cochrane analysis Not significant difference in the permeability and no 
effect in the clinical remission
Larazotide acetate Leffler et al[78] 342 adults with celiac 
disease who had been on 
a gluten free diet (GFD) 
for 12 mo or longer and 
maintained their current 
GFD during the study
Randomized, double-blind, 
placebo-controlled study 
assessed larazotide acetate 0.5, 
1, or 2 mg 3 times daily
Reduce signs and symptoms in celiac disease patients 
on a GFD better than a GFD alone
Table 2  Summary of the literature findings about therapies restoring intestinal permeability in irritable bowel syndrome
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GFD better than a GFD alone. Although the results 
were mixed, this study resulted in the successful use 
of a novel therapeutic agent targeting tight junction 
regulation in those patients with CeD who are sym-
ptomatic despite a GFD[78].
Therefore, the modulation of the tight junction 
could represent a paradigm shift in the treatment of 
immune mediated and inflammatory diseases (Celiac 
Disease, IBD, IBS, etc).
THERAPEUTIC TARGETS IN 
CONSTIPATION-PREDOMINANT 
IRRITABLE BOWEL SYNDROME
Constipation-predominant irritable bowel syndrome 
(IBS-C) is a frequent disorder and represents one of 
the main causes of ambulatory visits. Abdominal pain 
and discomfort characterize IBS-C, making it different 
from chronic idiopathic constipation[79]. 
It is now well known that treatment focusing only on 
bowel transit does not provide complete relief to patients 
with IBS-C. A global evaluation of the pathophysiology 
of IBS-C has led to the use of sensory end points like 
complete spontaneous bowel movements and the FDA 
combined end point (abdominal pain and complete 
spontaneous bowel movements) in clinical trials[79].
For example, new information on the mechanisms 
underlying pain sensation in chronic visceral hyper-
sensitivity as well as insights into the mechanism of 
action of new drugs targeting abdominal pain in IBS 
have recently been obtained by preclinical experiments 
in rodent models[80]. A number of drugs that we will touch 
upon in the next section are actually in development.
Linaclotide 
Linaclotide (MD-1100 acetate) is a novel orally active 
14-amino acid peptide of the guanylin family of cyclic 
guanosine monophosphate (cGMP)-regulating guanylate 
cyclase-C (GC-C) agonists. It has been approved by 
the FDA and by the EMA for the treatment of moderate 
to severe IBS-C in adults. Its action is focused on the 
increase of fluid secretion, favouring gastrointestinal 
transit, and has GC-C-mediated analgesic effects[81].
It is recommended at a dose of 290 μg orally once 
a day before meals. Linaclotide is converted to an 
active metabolite (MM-419447) that has the same 
pharmacodynamics and pharmacokinetics as the parent 
drug.
In 2007, Andresen et al[82] investigated the effect 
of 5 d of linaclotide on transit and bowel function in 
36 women with IBS-C according to Rome Ⅱ criteria 
randomized in a 1:1:1 fashion for placebo, linaclotide 
100 μg, and linaclotide 1000 μg.
Patients with slow colonic transit or slower transit 
than the mean for healthy controls were studied for 5 
d at baseline and 5 d during the treatment. Patients 
collected all the information regarding gastric, small 
bowel, and colonic transit by scintigraphy and bowel 
function using stool diaries, which included Bristol Stool 
Form Scale (BSFS) scores for stool consistency, ease of 
stool passage scores, and completeness of evacuation.
Linaclotide did not show any effect on gastric 
emptying or colonic filling. It did show a significant 
effect on ascending colon emptying t½ times (P = 0.015) 
and on overall total colonic transit times at 48 h (P = 
0.02) at the 1000 μg dose (P = 0.004), but not at the 
100 μg dose, as well as on increased stool frequency, 
decreased stool consistency, improved ease of passage, 
and acceleration of time to first bowel movement (P < 
0.001)[82].
In 2010, Johnston et al[83] investigated the efficacy 
and safety of 12 wk of linaclotide at a daily dose range 
of 75-600 μg in a phase Ⅱb randomized double-blind 
parallel-group multicentre placebo-controlled trial 
conducted on 420 patients with IBS-C (female patients 
= 92%). Patients had to meet Rome Ⅱ criteria, with 
fewer than three spontaneous bowel movements 
(SBMs) per week, and straining, lumpy/hard stools, 
or sensation of incomplete evacuation more than 25% 
of the time for at least 12 wk in the 12 mo preceding 
study entry. The primary endpoint was a change in the 
number of complete spontaneous bowel movements 
(CSBMs). Secondary endpoints were the effect on 
individual symptoms, quality of life (QOL), the number 
of patients who were CSBM responders (at least three 
CSBMs/wk and an increase of one CSBM from baseline 
for 75% of the study duration), and global relief res-
ponders (symptoms being somewhat, considerably, or 
completely relieved for 100% of the study duration or 
completely relieved for 50% of the study duration).
For the 75, 150, 300 and 600 μg linaclotide doses, 
the mean change in CSBMs per week was 2.90, 2.49, 
3.61 and 2.68, respectively (P < 0.01), and the per-
centage of patients who were CSBM responders was 
25%, 19.5%, 32% and 24%, respectively. Patients 
treated with linaclotide showed an adequate relief 
response (33%-51% vs 22%) and a global relief 
response (44%-55% vs 29%) compared to placebo. 
All doses of linaclotide significantly improved bowel 
habits, including frequency of short bowel movements 
(SBMs) (P ≤ 0.001) and CSBMs (P ≤ 0.01), severity 
of straining (P ≤ 0.001), stool consistency (P ≤ 0.001), 
and abdominal pain scores (P ≤ 0.05), than placebo. 
Abdominal discomfort, bloating, and global IBS-C 
measures were also improved for all doses except for 
the 75 μg (abdominal discomfort) and 150 μg (bloating) 
doses. The linaclotide effect was observed at the first 
week and lasted throughout the 12 wk of treatment. 
The approval of linaclotide for IBS-C was based on 
two randomized double-blind placebo-controlled phase 
Ⅲ trials similar in study design, end points, and patient 
demographics[84-86].
Primary end points included both the FDA-recom-
mended combined primary end point and a more 
rigorous combined primary end point that required 
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even more CSBM responses for 9 of 12 wk. Secondary 
end points included patient-reported abdominal pain, 
discomfort, and bloating; straining severity; and weekly 
SBM and CSBM frequency and stool consistency. The 
first phase Ⅲ trial included 804 adults with IBS-C who 
were randomized 1:1 to receive linaclotide 290 lg or 
placebo daily for 26 wk, with change-from-baseline 
end points measured at 12 and 26 wk[84]. Attrition rates 
were 18.5% at 12 wk and 25.6% at 26 wk. At 26 wk, 
the majority of patients withdrew from the study due 
to adverse events in the linaclotide arm (10.2%) and 
perceived lack of efficacy in the placebo arm (8.2%). 
Over 12 wk, the FDA combined primary end point was 
achieved by 33.7% of patients receiving linaclotide 
compared with 13.9% of patients receiving placebo (P 
< 0.0001).
Linaclotide was also superior to placebo in the 
more rigorous investigator-defined combined primary 
end point that was reached by 12.7% of linaclotide-
treated patients vs 3.0% of placebo-treated patients 
(P < 0.0001). At 26 wk, 32.4% of patients receiving 
linaclotide and 13.2% of patients receiving placebo 
(P < 0.0001) reached the FDA combined primary end 
point.
Improvements in all secondary end points occurred 
in the linaclotide group at weeks 12 and 26. The 
second phase Ⅲ trial of linaclotide was composed 
by a 12-wk treatment phase followed by a 4-wk 
randomized withdrawal phase[86]. A total of 803 adults 
with IBS-C were randomized to receive linaclotide 290 
lg or placebo once/d for 12 wk. Approximately 78% of 
patients completed the entire 16-wk study, and most 
of the patients who suspended the study did so due to 
adverse events in the linaclotide arm (7.9%). 
In the 12-wk active treatment phase, linaclotide 
demonstrated statistically significant improvements in 
all primary and secondary efficacy end points compared 
with placebo. Approximately one-third (33.6%) of 
patients receiving linaclotide fulfilled both components 
of the FDA end point compared with 21% of patients 
receiving placebo (P < 0.0001). Statistically significant 
improvements were observed also in abdominal pain, 
discomfort, and bloating in linaclotide-treated patients, 
with a mean reduction of about 2 points from baseline 
(on an 11-point scale) compared with reductions of 1.1 
with placebo (P < 0.0001 for each measure).
In the linaclotide arm, an improvement in severity 
of straining, constipation, and stool consistency was ob-
served compared with the placebo arm (all P < 0.0001). 
Linaclotide caused diarrhoea, abdominal pain, 
flatulence, headache, viral gastroenteritis, and abdo-
minal distension as adverse events. Diarrhoea, the most 
common, occurred in less the 20% of patients, probably 
due to increased fluid secretion and accelerated colonic 
transit[84,86].
In Johnston et al[83] phase Ⅱb dose-ranging trial, 
diarrhoea of mild to moderate severity was the primary 
dose-dependent adverse effect observed. It occurred 
in 11.4%, 12.2%, 16.5% and 18.0% of patients in 
the 75, 150, 300 and 600 μg linaclotide dose groups, 
respectively, compared with 1.2% in the placebo 
group. Dehydration or electrolyte disturbances were 
not found, although one instance of faecal impaction 
occurred[83]. In the studies by Rao et al[86] and Chey 
et al[84], 4.5%-5.7% of the linaclotide-treated patients 
and 0.2%-0.3% of the placebo group discontinued the 
study due to diarrhoea.
In a phase Ⅲ clinical trial in IBS-C, patients ex-
perienced adverse events more in the linaclotide 290-lg 
group (65.4%) than in the placebo (56.6%, P < 0.05) 
group[87]. In another IBS-C phase Ⅲ trial, adverse 
effects in the linaclotide group were reported at a 
similar rate to placebo (56.2% vs 53.0%, P = 0.39)[88]. 
Adverse events were reported by 60.5% of patients 
receiving linaclotide 145 lg, 55.7% of patients receiving 
linaclotide 290 lg, and 52.1% of patients receiving 
placebo[89].
In phase Ⅲ clinical trials in patients with IBSC, 
diarrhoea was the most frequently reported adverse 
event, occurring in 19.5%-19.7% of patients in the 
linaclotide groups compared with 2.5%-3.5% of 
patients receiving placebo (P < 0.0001). 
In randomized trials, linaclotide at 145 μg/d was 
best tolerated with improvement in CSBM/Wand 
symptoms in patients with CIC. Patients with IBS-C 
best responded to the 290-μg daily dose[84,85]. 
Linaclotide appeared to be very well tolerated. 
Linaclotide is approved for the treatment of IBS-C 
in both male and female adults at a dosage of 290 lg 
once/d and for the treatment of CIC at a dosage of 145 
lg once/d. The medication should be taken 30 min prior 
to breakfast. Renal or hepatic impairment is unlikely to 
affect the metabolism or clearance of linaclotide or its 
metabolite due to its low systemic exposure.
In conclusion, linaclotide can represent a targeted 
approach that addresses the complexity of symptoms 
associated with the syndrome. Linaclotide has been 
reported to safely improve IBS-C abdominal pain 
severity, bowel movement quality, and bowel move-
ment frequency as well as key symptoms of abdominal 
fullness, bloating, and discomfort, with associated 
improvements in QOL. Based on the United States 
FDA and the EMA, linaclotide fulfils the recommended 
endpoints with a number needed to treat (NNT) 
ranging from 4.39 to 7.9. It is effective and can be asso-
ciated with diarrhoea as the most common adverse 
effect leading to suspension of the medication in 
approximately 5% of patients. According to recent 
clinical evidence, linaclotide should be considered for 
patients with IBS-C due to its effect on abdominal pain 
and bowel symptom improvement.
Plecanatide 
Plecanatide is a 16-amino acid GC-C agonist currently 
used in phase Ⅲ clinical trials for CIC and phase Ⅱ 
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trials for IBS-C[90]. Plecanatide mimics the endogenous 
agonist of the GC-C receptor in the intestinal tract. 
Like that of uroguanylin, plecanatide’s actions are 
pH-dependent, with the most favorable efficacy in 
the acidic environment of the duodenum. Similar to 
linaclotide, plecanatide luminally activates the GC-C 
receptor on gastrointestinal mucosal epithelial cells, 
leading to intracellular secretory and extracellular 
anti-nociceptive effects via a cGMP-mediated second 
messenger pathway[91]. A phase Ⅲ randomized double-
blind trial in 951 patients with CIC treated with 0.3, 1 
or 3 mg plecanatide or placebo once/d for 12 wk was 
conducted[92]. The primary end points were weekly 
(more than three CSBMs/wk and an increase of more 
than one CSBM/wk from baseline) or an overall study 
response (weekly response for 9 of 12 wk, including 
3 of the last 4 wk to ensure durability of response). 
The percentage of overall responders was significantly 
higher in the plecanatide 3 mg group compared with 
placebo (19% vs 10.7%, P = 0.009). Weekly responder 
rates were also significantly higher in plecanatide 3 
mg than placebo for weeks 1-12. Patients treated with 
3 mg showed an improvement in stool frequency, 
consistency, straining, and quality of life compared with 
placebo. Data for other plecanatide doses were not 
shown.
Plecanatide potentially has low risk of adverse 
cardiovascular effects, as its systemic absorption is 
very low. According to the phase Ⅰ study for evalua-
tion of the safety and tolerability of plecanatide in 
humans[93], no measurable systemic absorption was 
observed at any doses of oral plecanatide. Plecanatide 
was safe and well tolerated up to the highest dose. 
Diarrhoea was the most prevalent side effect, but 
its frequency did not statistically significantly differ 
between placebo and plecanatide, and appeared not 
to be dose-related in the plecanatide-treated subjects. 
Other gastrointestinal events were nausea, abdominal 
discomfort and pain, and vomiting. In a Phase Ⅱ 
dose escalation trial involving a total of 84 chronic 
constipation patients recruited with modified Rome Ⅲ 
criteria, 14 d of plecanatide therapy improved stool 
frequency, stool consistency, straining and overall 
relief of chronic constipation symptoms. To confirm the 
safety and efficacy of plecanatide, two Phase Ⅲ trials 
(NCT01982240andSP304203-00) have been planned. 
In the United States and Canada, the Phase Ⅲ trial 
NCT01982240 was initiated in November 2013 with 
adult chronic constipation patients and was expected to 
be completed in February 2015[94].
Prucalopride 
Prucalopride is authorized in several countries (not in 
the United States) for women with CIC unresponsive to 
laxatives[95]. As a very highly selective 5-HT4 agonist, 
prucalopride has no measurable affinity for other 
receptors. In safety evaluation tests, prucalopride 
showed no h ERG (humanether-à-go-go-related gene) 
channel inhibitory activity. It is not arrhythmogenic, 
and it promotes colonic motility[96].
At dosages of 2 mg and 4 mg per day, this drug 
produced a low incidence of QT interval prolongation. 
Even up to 20 mg per day (10-fold higher than the 
recommended dosage), prucalopride displayed no 
clinically relevant effects on cardiovascular parameters 
in healthy volunteers. Prucalopride improved stool 
frequency and consistency, and it dose-dependently 
enhanced colonic transit in healthy controls or chronic 
constipation patients with no negative impact on gastric 
emptying or small bowel transit[97]. The patients’ quality 
of life was significantly improved by prucalopride 
treatment. 
In three pivotal trials, prucalopride showed a 
good efficacy in increasing CSBMs per week and in 
improving perceived disease severity and quality of life 
in patients with CC. A study conducted on 620 patients 
with CC treated with 2 or 4 mg of prucalopride for 12 
wk showed that it increased one or more CSBMs per 
week compared to the control group[98-100]. In another 
trial conducted on 713 patients with CC, 2 or 4 mg 
of prucalopride increased the frequency to three or 
more CSBMs per week and improved evacuation 
completeness, perceived disease severity, and quality of 
life[101]. In another study conducted on patients 65 years 
or older with CIC, prucalopride at a dose of 1 mg for 4 
wk did not cause any changes in an electrocardiogram 
or corrected QT (QTc) interval, showing its safety 
for the treatment of CIC in the elderly[97,102]. A study 
conducted on Asian subjects with CIC reported similar 
efficacy and safety as that observed in Western popu-
lations[103]. In a pooled analysis of the study with Asian 
subjects and the three pivotal trials, increased stool 
frequency of approximately three or more CSBMs 
per week was observed in Asian (34% vs 11%, P < 
0.001) and non-Asian (24.6% vs 10.6%, P < 0.001) 
women. Prucalopride was shown to be safe and well 
tolerated[104], improving CIC abdominal symptoms 
such as abdominal discomfort, bloating, straining, and 
painful bowel movements[105]. Another study conducted 
on a small number of patients showed the efficacy of 
prucalopride not only in the treatment of slow transit 
constipation but also of obstructed defecation and 
IBS-C[106].
In a recent analysis, Camilleri et al[106] evaluated 
the efficacy of prucalopride using the data from six 
phase 3 and 4 multicentre double-blind randomized 
placebo-controlled parallel-group trials performed across 
three continents.
Over the 12-wk treatment period, prucalopride-
treated patients consistently achieved a mean of 3 
SCBMs/wk compared to placebo with the treatment 
response observed in the individual trials[98-100,102]. On the 
other hand, the SPD555-401 trial was the only trial that 
failed to demonstrate a statistically significant effect of 
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prucalopride on this primary endpoint after both 12 and 
24 wk of treatment, without any plausible explanation 
of this lack of efficacy[107,108]. In the current study, no 
differences were found between men and women, 
although over time, a difference in the response rate 
has been reported. This could be related to differences 
in demographics (other than gender) and disease 
characteristics at baseline or to intrinsic differences 
in responsiveness to prucalopride between men and 
women. Furthermore, prucalopride was significantly 
more effective than placebo, as demonstrated by many 
secondary endpoints, including improvements in PAC-
SYM (Patient Assessment of Constipation Symptoms) 
and PAC-QOL (Patient Assessment of Constipation 
Quality of Life) scores and rescue medication use. An 
exploratory efficacy analysis showed that prucalopride 
treatment was effective even in patients with very 
severe CIC and those with no SBMs at baseline. 
In the current integrated analyses, the NNT with 
prucalopride used to achieve the primary efficacy 
endpoint in one patient was 8.8 (95%CI: 7.1-11.6). In 
a meta-analysis of data from three trials of linaclotide 
in patients with CIC, the NNT for the primary endpoint 
of these trials (3 SCBMs/wk and an increase of 1 
SCBM/wk, for 75 % of weeks) was 7 (95%CI: 5-8)[109]. 
Prucalopride has a favorable safety and tolerability 
profile[110]. Notably, no cardiovascular safety signals 
were observed. Indeed, the mean QT interval corrected 
according to Bazett’s formula (QTcB) and the mean 
QT interval corrected according to Fridericia’s formula 
(QTcF) were both/470 ms. A potential limitation of this 
integrated analysis is moderate heterogeneity (I2 = 
56%) due to a deviation of the results of one of the six 
trials compared to the others.
Prucalopride was well absorbed from the gastro-
intestinal tract, with an absolute oral bioavailability of 
more than 90%. Its main elimination route was via 
theurine (60%-70% excreted unchanged in the urine). 
Because prucalopride has a low level of metabolism by 
liver, its pharmacokinetics is unlikely to be altered by 
hepatic impairment, and no CYP3A4 drug interactions 
are anticipated. In Europe, 2 mg of prucalopride has 
been approved for the treatment of chronic consti-
pation in women who have no adequate response to 
laxatives[111].
Headache (in 25%-30%), nausea (12%-25%), ab-
dominal pain (16%-23%), and diarrhoea (12%-19%) 
were observed as adverse events. 
Recently, a randomized trial compared prucalopride 
with Macrogol/PEG 3350 plus electrolytes in patients 
with CIC. Prucalopride showed a non-inferiority for 
the primary outcome, even though PEG showed a 
superiority in improving gastrointestinal transit, stool 
frequency, and number of spontaneous bowel move-
ments[112]. Although no studies have yet evaluated the 
efficacy of prucalopride in IBS-C, it is expected that 
it may also be efficacious for the disease symptoms. 
However, the worsening of abdominal pain may limit its 
use in clinical practice.
YKP10811
YKP10811 is a novel substituted benzamide derivative, 
small molecule with high binding affinity to the 5-HT4 
receptor[113]. In cellular functional assays conducted with 
the 5-HT4 receptor, YKP10811 showed weak agonist 
activity that was dose dependent and reproducible. 
These results indicated that YKP10811 acts as a partial 
agonist of the 5-HT4 receptor. YKP10811 did not 
show any significant off-target binding to any other 
receptors, enzymes, or serotonin-receptor subtypes at 
1 mmol/L, except for binding to the 5-HT2A receptor 
and the 5-HT2B receptor. Thus, YKP10811 has 120-fold 
and 6-fold lower affinity, respectively, for 5-HT2A 
and 5-HT2B receptors than for 5-HT4. In cellular 
functional assays, YKP10811 showed antagonist 
activity at the 5-HT2B receptor with a median inhibitory 
concentration. In rats, YKP10811 accelerated colonic 
transit by 37% at a dose as low as 1 mg/kg. In dogs, 0.3 
mg/kg YKP10811 accelerated colonic transit by 45.5% 
at 2 h after dosing. The accelerated colonic transit in 
dogs was associated with significantly increased colon 
contractions and defecation. YKP10811 significantly 
reduced visceral hypersensitivity in multiple pain 
models in rats. In a phase Ⅰ double-blind randomized 
9-d placebo-controlled multiple-ascending dose study 
in healthy volunteers at doses of 5, 15, 30 and 45 mg 
once daily, YKP10811 was well tolerated with minimal 
side effects. In a single-center randomized parallel-
group double-blind placebo-controlled study[114] in 
patients with functional constipation, YKP10811 
enhanced gastrointestinal and colonic transit and 
improved bowel function during an 8-d treatment trial. 
The effect of YKP10811 on colonic transit was mirrored 
by improvements in softer stool consistency and 
faster time to first bowel movement, suggesting that 
YKP10811 has encouraging effects on these clinical 
end points. In addition to pharmacodynamic effects in 
patients with functional constipation, improvements 
in bowel functions are validated and measurable end 
points recommended for the treatment of functional 
constipation[115]. These findings suggest that YKP10811 
may be a potential new medication for the treatment 
of functional constipation. YKP10811 had a robust 
effect on accelerating, by 30% to 40%, colonic emp-
tying when compared with placebo. Ascending colon 
emptying has been reported to have the greatest 
contribution to overall colonic transit[116] because 
the ascending and transverse colon constitute the 
“reservoir” or storage regions of the human colon[117]. 
Among the other 5-HT4-receptor agonists previously 
studied with the same method, 4 mg prucalopride 
and 30 and 50 mg velusetrag[118] also accelerated AC 
emptying. Emptying of the proximal colon correlates 
linearly with faecal weight[119], which largely reflects 
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stool water content, and as expected based on prior 
studies, the overall colonic transit was correlated 
linearly with stool consistency, with less significant 
association with the number of bowel movements per 
day. The results also showed the dual action (agonist/
antagonist) of YKP10811 seen in in vitro studies. 
YKP10811 facilitated the electrical field stimulation-
induced neurogenic twitch of guinea pig ileum at lower 
concentrations. This type of dual action (agonist/
antagonist) of YKP10811 under the same assay 
conditions was also shown in the peristaltic reflex test, 
with an EC50 of 0.5 mmol/L and an IC50 of 21 mmol/L. 
There is a significant gap in concentration ranges 
(> 40-fold difference) for stimulatory vs inhibitory 
effects of YKP10811 in vitro (unpublished data; SK Life 
Science, Inc). Two participants, 1 receiving placebo 
and 1 receiving 20 mg YKP10811, had prolonged QTc 
(> 470 ms). Both participants discontinued the study 
on the advice of the investigators, even though the 
QTc prolongation was minimal (functions in patients 
with functional constipation). Thus, YKP10811 is 
likely to be of benefit to patients with functional 
constipation without rectal evacuation disorders. 
The safety and efficacy of this novel agent should be 
studied in larger multicentre clinical trials. With further 
studies, the current data suggest that YKP10811 
would expand the therapeutic options beyond the 
recently approved secretagogue medications for the 
treatment of functional constipation, lubiprostone and 
linaclotide[120,121].
YKP10811 was reported to be safe and tolerable 
in healthy volunteers. Except for a Phase Ⅱ clinical 
trial in C-IBS patients (NCT02082457)[122], there were 
only two registered Phase Ⅱ trials that evaluated 
the efficacy and safety of YKP10811 in comparison 
with placebo in subjects with CIC (NCT015 23184, 
NCT01989234)[123,124]. Collectively, 420 eligible subjects 
were enrolled to be treated with different doses of 
YKP10811 or placebo once daily for 8 d and 12 wk in 
two trials. The results have not been completed for 
reporting yet. This drug is pending to pass Phases Ⅱ 
and Ⅲ of clinical trials, expected in 2016.
Renzapride
Renzapride (a novel benzamide substitute) is a full 
agonist for the 5HT4 receptor and an antagonist to 
5HT2b and 5HT3 receptors. It can accelerate the 
gastrointestinal tract transit and motility stimulating 
the 5HT4 and 5HT2b receptors[125], and it appears to 
be a promising therapeutic agent for constipation, 
which is predominant in IBS patients. It is safe and 
has only a few adverse effects[126,127]. Several clinical 
trials have been performed to evaluate its potential 
efficacy in IBS patients, confirming that renzapride 
does not cause cardiac arrhythmias in clinical doses, 
unlike cisapride[126,127]. It is excreted renally and is 
not metabolized by cytochrome P450 enzymes. 
Thus, no drug interactions via affecting cytochrome 
P450 enzymes have been reported[125,127]. Renzapride 
stimulates colonic transit and reduces transit time 
and pain in IBS patients due to its prokinetic pro-
perty, providing a benefit in those patients with 
constipation[128]. In addition, a dose-dependent efficacy 
of this drug has been demonstrated[126]. In a phase Ⅱ 
study of 46 women with IBS-C, renzapride at a dose 
of 4 mg q.d. favoured colonic transit and increased 
ascending colon emptying compared to placebo[129]. A 
large multicentre European trial confirmed the effects of 
4 mg renzapride q.d. in the improvement of frequency 
of bowel movements and stool consistency in IBS-C[130]. 
Much pharmacodynamic data support renzapride’s 
prokinetic effects. As for the prior European study, 
statistically significant differences in the frequency 
of bowel movements and stool consistency in favour 
of renzapride 4 mg q.d. were relatively small. In 
addition, renzapride did not improve the feelings of 
completeness of bowel movements or the amount of 
straining. Several systematic reviews have shown the 
efficacy of 5HT receptor modulators in IBS patients. 
In 2009, Ford et al[131] conducted a meta-analysis by 
reviewing placebo-controlled clinical trials up to 2008 
on the efficacy of known 5-HT3 antagonists and 5-HT4 
agonists in IBS. They observed that renzapride and 
cisapride were not more effective than placebo in IBS 
patients. 
Other investigators also evaluated the efficacy of 
combined 5HT3 antagonists/5HT4 agonists (cisapride 
and renzapride) in IBS patients[132] and observed that 
1 and 2 mg of renzapride was ineffective in relieving 
IBS symptoms, supporting the results obtained by 
Ford. However, these authors showed that 4 mg 
of renzapride was significantly more effective than 
placebo. 
Recently, a meta-analysis[133] from randomized 
placebo-controlled clinical trials, including 2528 C-IBS, 
non-C-IBS, and non-D-IBS patients according to the 
Rome criteria, was performed. The study confirmed 
that renzapride had no significant effects in relieving 
symptoms in IBS patients compared to placebo. To 
reach a convincing conclusion on the effectiveness 
of renzapride, a clinical trial compared with placebo 
was performed. Renzapride at a dose of 4 mg was 
compared to placebo for 5 wk or less and more than 
5 wk. Although the differences were not statistically 
significant, the results were clinically important and 
significant for both treatment durations. Therefore, 
these results could be considered for renzapride 4 mg, 
while more trials are necessary to determine the effec-
tiveness of this novel drug more precisely. As regards 
adverse effects, no statistically significant differences 
between renzapride and placebo were found, except 
for diarrhoea occurrence, which was higher in patients 
treated with renzapride. In addition, renzapride 
caused more withdrawals due to adverse effects and/
6605 September 28, 2017|Volume 23|Issue 36|WJG|www.wjgnet.com
Sinagra E et al . New therapeutic perspectives in IBS
6606 September 28, 2017|Volume 23|Issue 36|WJG|www.wjgnet.com
study that compared in vivo activity of velusetrag vs 
tegaserod in guinea pig, the subcutaneous admini-
stration of velusetrag increased colonic transit more 
than tegaserod did. Velusetrag was more potent than 
tegaserod when orally administered in a dog GI smooth 
muscle contractility model[142]. Velusetrag exhibited 
an acceptable oral bioavailability in rats and dogs[140], 
while the systemic effect of the drug was increased by 
an increase in the administered dose in healthy volun-
teers[143-145]. Both single (up to 70 mg) and multiple 
(up to 50 mg, for 2 wk) dosing of velusetrag in healthy 
subjects showed a dose-dependent effect on GI 
motility[145].
There have been two Phase Ⅱ clinical trials to 
evaluate the clinical efficacy of this drug. In one of 
these two studies[138], 60 healthy volunteers were 
randomly assigned, in double-blind fashion, to placebo 
or 5, 15, 30 or 50 mg velusetrag, with transit measure-
ments after single and 6-d dosing.
The GI transit was evaluated in a randomized 
double-blind placebo-controlled study conducted on 
60 healthy subjects randomly assigned to receive 
velusetrag at a dose of 5, 15, 30 or 50 mg or placebo 
either as a single dose or for 6 d[137]. Velusetrag at 
single dose (30 and 50 mg) favoured colonic transit, 
evaluated by colonic filling at 6 h and geometric center 
at 24 h, while this effect was not observed in patients 
treated with placebo. Similarly, velusetrag at multiple 
doses (15-50 mg doses) favoured gastric emptying 
compared with placebo (P = 0.002). In this study by 
Manini et al[115], an improvement of stool frequency 
and consistency by velusetrag in a subset of 11 
patients with chronic constipation was also reported. 
Pharmacokinetic evaluations demonstrated a similar 
profile in healthy and CIC subjects[143]. Velusetrag was 
well tolerated in the Phase I study when administered 
in single and repeated doses in healthy subjects. In 
the Phase Ⅰ clinical trial, the most commonly reported 
adverse event was diarrhoea, which is expected 
because of velusetrag’s mechanism of action[141,143]. In a 
Phase Ⅱ randomized, double-blind, placebo-controlled 
trial, the efficacy and safety of velusetrag were com-
pared with placebo in 401 subjects with CC. SBM 
frequency, CSBM and other associated symptoms with 
CIC were significantly improved compared with placebo 
in patients who received velusetrag for 4 wk. The 
most effective dose was 15 mg once daily. Most of the 
adverse events, such as diarrhoea, headache, nausea 
and vomiting, were mild to moderate. These adverse 
events were common in the first days of treatment 
with the dose of 50 mg once daily. The number of 
withdrawals due to adverse events was 18 vs 1 for the 
velusetrag- and placebo-treated subjects, respectively. 
The number of withdrawals were 4, 3 and 11 in the 
15-, 30- and 50-mg treated groups, respectively. 
However, the medicine was well tolerated with no 
cardiac complications[146]. Another Phase Ⅱ study of 
or low efficacy in patients. One of the limitations of 
this meta-analysis was the evaluation of trials with 
different patient inclusion criteria (age, sex, lifestyle 
and compliance). In addition, the trials evaluated had 
different durations of treatment and endpoints. The 
treatment durations ranged from 2 wk[134] to 12 wk[135]. 
To avoid heterogeneity, patients were divided into two 
groups according to treatment duration and time of 
reporting the results (5 wk or less and more than 5 
wk), although there were few data in each group. The 
safety data from these phase Ⅲ studies indicated that 
renzapride was generally well tolerated, even though 
ischaemic colitis was reported in the long-term study 
in 3 patients. However, evaluating the total of patients 
treated with renzapride during the study, the overall 
rate of ischaemic colitis appeared comparable with 
that reported for other 5-HT3 receptor antagonists[136]. 
In conclusion, renzapride is not only superior to 
placebo in relieving IBS symptoms (abdominal pain and 
discomfort), but it also causes increased diarrhoea 
occurrence compared with placebo and appears to 
be associated with many drop-outs. Therefore, this 
drug might be a cost burden to patients, without any 
advantages in efficacy. Indeed, during the trial, no 
improvements in frequency of bowel movements, 
straining, or completeness of evacuation were observed 
in patients treated with renzapride. Taken together, 
these data suggest that renzapride is unlikely to provide 
clinically meaningful improvement in IBS symptoms.
Velusetrag
Velusetrag is an orally administrated available 5-HT4 
agonist developed by Theravance. The binding affinity 
of this drug for the 5-HT4 receptor is more than 
500-fold that of other 5-HT receptor subtypes[137]. 
The major metabolite detected in plasma after oral 
velusetrag is THRX-830449, which is a full agonist and 
is approximately equipotent to velusetrag. Metabo-
lism occurs through the CYP3A4 system. In healthy 
subjects[138], at steady a state, the THRX-830449 to 
velusetrag AUC ratio is approximately 0.5 following 
once-daily dosing of velusetrag (15 mg). 
Increased smooth muscle contractility of the 
antrum, fundus, duodenum and jejunum was observed 
in velusetrag-treated dogs[139]. Velusetrag increased 
guinea-pig colonic transit and produced dose-depen-
dent relaxation of the rat esophagus[140]. Relief of 
constipation using velusetrag was also confirmed in 
chronic constipation patients[141].
Velusetrag was approximately 6- or 86-fold more 
potent than cisapride or mosapride after intravenous 
dosing and 9- or 18-fold more potent than teg-
aserod or cisapride, respectively, after intraduodenal 
administration[141].
Its low risk for cardiovascular events has been 
confirmed in an in vitro investigation demonstrating no 
effect on hERG channel conductance[140]. In a preclinical 
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velusetrag in 401 patients with chronic constipation 
treated for 4 wk showed that there were significant 
treatment effects on the average daily number of bowel 
movements compared with placebo[147].
The most common adverse effects of velusetrag 
were those frequently associated with 5-HT4 agonists, 
including diarrhoea, headache and nausea. These 
dose-dependent adverse effects were mild to moderate 
and usually occurred within the initial days of dosing. 
Clinically relevant doses of velusetrag in animals or 
humans did not generate severe side effects on blood 
pressure, heart rate or electrocardiogram. In isolated 
porcine or canine coronary arteries, velusetrag showed 
no contractile activity[148]. In the randomized, double-
blind, placebo-controlled study in 60 healthy subjects, 
there was no significant treatment effect on heart rate 
recorded by ECG after treatment for the prior 5-6 d. In 
this study, there were also no serious adverse events, 
and predictable GI effects such as diarrhoea and 
altered bowel movement were the main adverse events 
recorded[140]. These results suggest that velusetrag 
appears to be well tolerated. Further careful clinical 
studies will be required to further evaluate the safety 
and tolerability of this drug.
Naronapride
Naronapride (ATI-7505)[149] is a benzamide 5-HT4 
receptor agonist that activates 5-HT4 receptors but 
has almost no actions on the other 5-HT subtypes. 
The design of ATI-7505 was based on the prototypical 
agent, cisapride. However, unlike cisapride, which 
is a mixture of (3R, 4S) and (3S, 4R) isomers of 
substituted piperidine-based scaffolds, ATI-7505 is 
the pure (3S, 4R) isomer. ATI-7505, with its (R)-
quinuclidinyl moiety, is metabolized by ubiquitous 
carboxyl esterases to a single metabolite, ATI-7500. 
This potent and selective 5-HT4 receptor agonist 
showed different pharmacodynamic and pharma-
cokinetic properties from previous nonselective 5-HT4 
agonists. Hydrolytic esterase metabolism, unlike 
oxidative CYP450 metabolism, is a large-capacity 
metabolic system that can easily handle therapeutic 
amounts of xenobiotics. This large-capacity system 
implies that other drugs metabolized by esterases 
are not expected to induce drug-drug interactions of 
ATI-7505 with other drugs. There is also no interaction 
with drugs metabolized by a different enzymatic 
system, such as CYP450[150]. Naronapride is not 
metabolized by CYP450 enzymes, and thus, less drug-
drug interaction occurs. 
A thorough QT study showed that naronapride had 
no obvious effect on cardiac repolarization at either 
therapeutic or supratherapeutic doses. The structure of 
naronapride is similar to that of cisapride, but it is more 
selective than cisapride and thus interacts minimally 
with hERG channels and 5-HT3 receptors[150]. ATI-7500, 
the main metabolite of naronapride, is 100-fold less 
active than the parent drug. Unlike prucalopride and 
velusetrag, neither naronapride nor ATI-7500 can 
pass the blood-brain barrier, therefore reducing the 
incidence of side effects. This new benzamide exhibited 
GI prokinetic effects, stimulated colonic transit and 
reduced stool consistency in healthy male and female 
subjects[151]. One Phase Ⅱ randomized double-blind 
placebo-controlled dose definition study evaluated 
several doses of orally administered naronapride (20, 
40, 80 and 120 mg twice a day) in 210 patients with 
CC. This study evaluated the clinical effects of 9 days’ 
treatment with three doses of ATI-7505 at 3, 10 and 
20 mg on GI and colonic transit using a validated 
scintigraphic method. There were borderline effects 
on gastric emptying at half-time. However, ATI-7505 
stimulated colonic transit at 24 h and ascending 
colonic emptying. There was looser stool consistency 
as measured by the Bristol stool form scale with the 
10- and 20-mg t.i.d. doses. This finding suggests that 
ATI-7505 appears to have prokinetic properties in both 
stomach and colon in healthy subjects and, particularly, 
in the colon. Further clinical trials of larger numbers of 
patients with functional gastrointestinal disorders, such 
as patients with CIC, are required to evaluate clinical 
efficacy.
The inhibition of the delayed rectifier K+ current 
in response to ATI-7505 in patch-clamped HEK293 
(human embryo kidney) cells transfected with the 
human IKr channel is very weak, suggesting that there 
would be an adequate safety window between activity 
in the GI tract and potential cardiac toxicity. In addition, 
the primary metabolite ATI-7500 is 100-fold less 
active than the parent drug at the 5-HT4 receptor and, 
as with ATI-7505, has no detectable HERG channel 
inhibitory activity at concentrations up to 100 μmol/L. 
Preliminary data on intensive cardiac safety monitoring 
suggest that ATI-7505 is safe as regards the cardiac 
profile[149].
The most common drug-related adverse events 
were headache, diarrhoea, nausea and vomiting. 
Headache and abdominal pain were reported more 
frequently by the maximum dose of naronapride[152].
Chenodeoxycholic acid
Chenodeoxycholic acid (CDCA) is a bile acid that can 
induce colonic electrolyte secretion by acting on the 
membrane-bound bile acid GPBA receptor (TGR5) on 
enterocytes, subsequently leading to the stimulation of 
cAMP generation and electrogenic chloride secretion. 
Supplementation with specific bile acid analogues or 
by using drugs that inhibit ileal bile acid reabsorption 
may benefit constipation patients.
Oral chenodeoxycholic acid at doses of 750-1000 
mg/d can increase bowel movements, decrease stool 
consistency, and reduce the time to defecation in 
IBS-C[153].
They were previously used for the dissolution of 
Sinagra E et al . New therapeutic perspectives in IBS
6608 September 28, 2017|Volume 23|Issue 36|WJG|www.wjgnet.com
gallstones, and they are known to favour diarrhoea 
at high doses in healthy controls and constipation 
patients[154]. The effects of CDCA on gastrointestinal 
and colonic function have been evaluated in healthy 
volunteers and patients with irritable bowel syndrome 
with constipation. In a randomized controlled trial, 
500 mg and 1000 mg CDCA given to 60 healthy 
volunteers for 4 d led to dose-dependent acceleration 
of colonic transit. In addition, significant increases in 
stool frequency, decreases in stool consistency, and 
improvements in ease of stool passage were reported 
with CDCA[155]. In a double-blind placebo-controlled 
study, Rao et al[153] demonstrated that sodium chen-
odeoxycholate[156] stimulated colonic transit and 
improved bowel function in 36 women with irritable 
bowel syndrome with constipation. Increased stool 
frequency, greater ease of stool passage and looser 
stool consistency were observed in patients treated 
with sodium chenodeoxycholate 500 mg or 1000 mg 
for 4 d as compared with controls. Unfortunately, over 
40% of sodium chenodeoxycholate-treated patients 
had light abdominal cramping or pain. Whether these 
side effects could be mitigated at a lower dose remains 
to be determined.
Elobixibat
Elobixibat is an orally administrated available potent 
inhibitor of ileal bile acid transporter with minimal 
systemic exposure[157]. Elobixibat (A3309) reduces bile 
acid enterohepatic recirculation and upregulates bile 
acid synthesis as measured by serum C4 levels. It also 
depletes liver cholesterol and reduces serum LDL[158], 
thus increasing the delivery of bile acids to the proximal 
colon, which in turn increased fluid secretion, colonic 
motility and stool frequency, and it improved stool 
consistency and relieved constipation-related symptoms 
in chronic idiopathic constipation patients[159,160].
In a phase Ⅰ trial, elobixibat stimulated colonic 
transit in a dose-dependent way. In a randomized 
phase Ⅱ trial, elobixibat at doses of 15 and 20 mg/d 
showed an improvement of stool consistency and of 
stool passage, increased the number of SBMs and 
reduced straining in female patients with CIC[161]. In 
a dose-finding randomized trial, elobixibat increased 
C4, reduced LDL cholesterol, increased colonic transit 
from 3 to 1.9 d and increased the number of SBM 
and CSBM/wk in patients with CIC compared to 
placebo. The treatment with elobixibat also resulted 
in an improvement of bloating severity, but no effects 
on abdominal pain or discomfort were reported[157]. 
The well-tolerated doses were 5-10 mg, with a 
discontinuation rate during the phase IIb trial of 13%, 
rising to 23% for the 15 mg group. Fifty-four percent of 
patients developed adverse events, such as abdominal 
cramps, relieved by defecation, and diarrhoea. 
However, the side effects were not different from those 
of the placebo group[162]. In a large randomized trial 
conducted on patients with CIC, the 10- and 15-mg 
doses increased SBMs and reduced the time to SBM 
(12 h with the 10-mg dose, 7 h with the 15-mg dose 
and 24 h with the placebo). In patients treated with 
elobixibat, an increased spontaneous laxation within 24 
h was observed compared with placebo (75 % on 15 
mg/d and 45 % on placebo).
The side effects of elobixibat are mainly gastro-
intestinal tract-related. Although higher dosages 
of elobixibat caused abdominal pain and diarrhoea 
more frequently, no severe adverse effects occurred 
in the Phase Ⅰ and Phase Ⅱ clinical trials. The Phase 
Ⅲ clinical trials are ongoing to determine the best 
tolerated dose and to examine the effects of long-term 
administration.
Complete spontaneous bowel movements per week 
increased in a dose-dependent way. An improvement 
of stool consistency and bloating was observed at the 
10- and 15-mg doses. Side effects such as abdominal 
pain and diarrhoea were also dose-dependent, notably 
for the 15-mg dose[157].
Elobixibat is a promising anti-constipation drug. 
However, there are no studies in cancer or in OIC (opioid 
induced constipation) patients. Due to its prokinetic 
activity, elobixibat is not recommended in patients with 
mechanical bowel obstruction.
According to the results of Phase Ⅱ trials in chronic 
idiopathic constipation patients, elobixibat was safe 
and generally well to lerated, even at a dose up to 20 
mg per day.
As illustrated by elobixibat, the advantages of 
IBAT inhibitors may be especially attractive, which 
may boost research on other IBAT inhibitors, such as 
SC-435, S-8921 and S-0960[163-165].
Lubiprostone
Lubiprostone, a first-in-class drug for the treatment 
of chronic idiopathic constipation and irritable bowel 
syndrome in adult women with constipation is believed 
to be a highly selective locally acting activator of 
ClC-2 channels[166]. Lubiprostone can tautomerize 
between the inactive form Ⅰ and the active form Ⅱ[167]. 
Lubiprostone acts mainly by activating specific type-2 
chloride channels (ClC-2) on the apical membrane 
of the enterocytes[166] that are involved in ion and 
fluid transport across the epithelial membrane. Once 
channels are opened, chloride enters the enterocyte 
in the basal membrane through the action of Na-K-
2Cl active cotransporters. This mechanism results 
in an electrochemical gradient favouring chloride 
secretion. It leads to an overall concentration-
dependent raise in intestinal fluid secretion without 
any impairment on serum sodium and potassium 
levels. These mechanisms explain how lubiprostone 
increases the number of colonic spontaneous bowel 
movements per week. However, lubiprostone efficacy 
on the abdominal pain score is only partially known 
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and needs further investigation. Lubiprostone also 
activates a prostaglandin receptor (EP4), which in 
turn activates cystic fibrosis conductance regulators 
(CFTR)[168]. The activation of EP4 receptors favours 
colonic smooth muscle and gastric longitudinal muscle 
via vagal nerve endings[169]. Lubiprostone changes 
mucin, which improves the gut microbiome, creating an 
anti-inflammatory environment[170]. Unlike linaclotide, 
lubiprostone does not increase pain thresholds[171].
Lubiprostone pharmacokinetics is not impaired by 
renal failure. However, great adverse events with a 
standard dose of lubiprostone can result in cases of 
mild-to-moderate hepatic impairment (Child-Pugh class 
A and B), which increases the lubiprostone metabolite 
M3. Thus, in cases of liver impairment, a reduction of 
lubiprostone starting doses is required. Lubiprostone 
metabolism does not involve cytochromes. The cata-
bolism is mediated by carbonyl reductase in the 
stomach and jejunum[172]. Lubiprostone is unlikely to 
have major drug interactions.
In healthy subjects, a reduction in gastric emptying, 
an increase in gastric fasting volume, a reduction in 
maximum tolerated gastric volumes and a stimulation 
of small bowel and colon transit was observed with 
lubiprostone at a dose of 24 μg twice daily[173]. However, 
the effects on gastric motility may mask the nausea 
side effect.
Two 12-wk double-blind randomized multicentre 
placebo-controlled phase Ⅲ clinical trials[174] and one 
36-wk open-label extension study[175] contributed to 
the FDA’s approval of lubiprostone for the treatment 
of IBSC in women. A total of 1171 patients were 
randomized 2:1 to receive either 8 μg lubiprostone 
or placebo twice/d. The primary end point of each 
study was the evaluation of response rate, measured 
by patient-reported improvements from baseline in 
IBS-C symptoms. As secondary end points, monthly 
responder rates, changes from baseline in SBM 
frequency, stool consistency, straining, distention, 
abdominal pain/discomfort (each measured on a 5-point 
Likert scale) and change in health-related quality of life 
were evaluated.
The discontinuation rate in both studies was 24%, 
firstly due to withdrawal of consent and secondly to 
adverse events and perceived lack of efficacy. Lubipro-
stone was superior in the primary end point compared 
to placebo (17.9% vs 10.1%, P = 0.001). Patients 
treated with lubiprostone reported more improvements 
in all secondary end points than placebo. Lubiprostone 
was associated with a more significant improvement in 
abdominal pain/discomfort than placebo from baseline 
to month 2 (0.43 vs 0.35, P = 0.039) and month 3 (0.45 
vs 0.36, P = 0.028).
Lubiprostone significantly changed the mean SBM 
frequency from baseline to month 1 compared with 
placebo, even though the numerical data were not 
included.
Two 4-wk phase Ⅲ randomized double-blind 
placebo-controlled multicentre clinical trials were 
conducted on a total of 479 patients to evaluate the 
short-term efficacy and safety of lubiprostone in 
patients with CIC with identical study designs and 
primary end points. After a 2-wk baseline period, 
eligible subjects received 24 lg lubiprostone or placebo 
twice/d.
The number of patient-reported SBMs, defined as 
any BM occurring 24 h or longer after the use of an 
alternative drug used to relieve constipation (rescue 
medication), during the first week of treatment was the 
primary end point of each study[176,177]. Lubiprostone 
was associated with a statistically higher frequency of 
SBMs during the first week of treatment than placebo. 
Improvements in other secondary end points, 
such as stool consistency, straining, and constipation 
severity were also observed in patients treated with 
lubiprostone compared with placebo in all 4 wk in 
both studies. However, significant improvement in 
abdominal distention and discomfort compared with 
placebo was not observed in either study.
As regards side effects, a similar percentage of 
patients reporting at least one treatment-related 
adverse event for IBS-C was observed in the lubi-
prostone (50%) and placebo (51%) groups. The most 
common side effects were gastrointestinal (19% with 
lubiprostone vs 14% with placebo). Serious adverse 
events were similar between the two groups (1%). 
Nausea was the most frequent treatment-related 
event[11,12], although it may be reduced by administering 
lubiprostone with meals.
A unique adverse effect occurred with the initial 
dose. In rare cases, acute transit dyspnea and ischemic 
colitis were observed[176,178].
Caution in the use of lubiprostone should be used 
for infants of breastfeeding mothers due to the risk 
of diarrhoea[179]. Limited data are available on the 
lubiprostone effects in paediatric patients, and further, 
larger studies are required. In an open-label 4-wk 
clinical trial conducted on paediatric patients with 
CIC (mean age 10.2 years)[179], lubiprostone was 
efficacious and well tolerated at daily doses of 12-48 
lg. The recommended dose of lubiprostone for the 
treatment of CIC in both adult men and women is 24 
lg twice/d, while for the treatment of IBSC in adult 
women, it is 8 lg twice/d. Due to its minimal systemic 
absorption and its metabolism through a cytochrome 
P450-independent pathway, lubiprostone-drug interac-
tions are unlikely, even though in vitro studies have 
suggested that methadone may decrease the efficacy 
of lubiprostone by reducing chloride channel type 2 
activation[179].
In patients with moderate or severe hepatic 
impairment (Child-Pugh class B or C), a dose reduction 
might be suggested, while in patients with renal 
failure, no dosage adjustment is recommended. 
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A small percentage (8%-13%) of patients over 65 
years were included in clinical trials with lubiprostone. 
The safety profile was similar in elderly and younger 
patients, even though, due to the limited the number 
of patients over 65 years, no differences in clinical 
response were observed[179], and further studies are 
needed.
Like linaclotide, lubiprostone is contraindicated 
in mechanical bowel obstruction. To confirm the 
indications in the treatment of IBS-C in adults, more 
and larger trials are required. Due to the chronic nature 
of IBS-C and CIC, post-marketing studies are necessary 
to confirm the long-term efficacy and safety of lubi-
prostone. All randomized clinical trials were of limited 
duration (12-26 wk). However, in open-label extension 
studies, a safety over 52 wk was demonstrated.
Despite the efficacy, the side effects (e.g., nausea, 
abdominal pain) and the high cost may limit the use of 
lubiprostone.
Tenapanor
Tenapanor, also known as AZD1722 or RDX5791, is a 
first-in-class orally available inhibitor of NHE3 that is 
minimally absorbed in the gastrointestinal tract-this 
constitutes a significant therapeutic benefit, as it may 
act on the drug target[180,181]. Consequently, tenapanor 
increases intestinal Na+ contents, which leads to an 
increase in intestinal fluid volume and accelerates 
the whole GI transit, as shown in rats. Moreover, 
tenapanor inhibits the absorption of phosphorus, which 
is independent of typical phosphorus transporters in 
the intestines, namely, sodium-dependent phosphate 
transport protein 2B (NaPi2b) and Na (+)-dependent 
phosphate transporter (PiT1). Tenapanor is stable 
at room temperature and is formulated into tablets 
ranging from 1 to 50 mg. Absorption, distribution, 
metabolism and excretion (ADME) studies have 
revealed that tenapanor is minimally absorbed and 
metabolized. For example, experiments in rats showed 
92.2% ± 1.6% recovery of tenapanor in faeces 
upon oral administration[182]. In humans, the inactive 
metabolites of tenapanor were found in plasma, 
but they were only approximately 9% of the parent 
compound. In pharmacokinetic studies, tenapanor was 
observed at relatively low concentrations in plasma 
(average < 3 ng/mL) of rats and dogs, but only 
sporadically (29/76 and 0/92, respectively).
Oral administration of tenapanor (at doses of 0.1 
and 3 mg/kg) produced a dose-dependent increase in 
faecal water content and stool consistency in rats. The 
effect of tenapanor at a dose of 50 mg/kg twice daily 
on stool form was assessed in cynomolgus monkeys. 
The animals were observed for 4 d before treatment. 
Soft or watery stools were observed in monkeys 
on tenapanor treatment, and stool consistency 
was normalized on day 6 of the experiment. Under 
physiological conditions, tenapanor given orally at 
doses of 3, 10, 30 and 50 mg/kg did not affect visceral 
sensitivity or the changes in intestinal volumes induced 
by colorectal distension in comparison with the control 
and tegaserod-treated (5 mg/kg administered per os) 
groups[183]. However, tenapanor (30 and 50 mg/kg) 
had a dose-dependent antinociceptive effect in the 
acute restraint stress-induced intestinal hypersensitivity 
to colorectal distension. The antinociceptive potential of 
tenapanor was comparable with that of the tegaserod-
treated group. 
The safety and tolerance of tenapanor were 
assessed in a randomized, double-blind, placebo-
controlled study[184,185]. Eighty healthy volunteers were 
included in the study (male and female). Tenapanor 
was given orally at the doses ranging from 10 to 900 
mg (as a single administration) and for 7 consecutive 
days at doses ranging from 3 to 100 mg to assess 
the safety of tenapanor administration. Tenapanor 
was also beneficial for the percent of days with a 
spontaneous bowel movement. Finally, no serious 
side effects were observed, and there were very few 
adverse events[186]. Phase Ⅱa In a Ⅱa double-blind 
randomized placebo-controlled study on 181 patients 
with IBS-C[187], tenapanor was given orally at doses of 
10, 30 and 100 mg once daily for 4 consecutive weeks 
with 2 wk follow-up. The primary end point (change 
in complete spontaneous bowel movements from 
baseline to week 4) was not met in this study, and the 
incidence of diarrhoea was comparable with that of the 
placebo group. However, an improvement in bloating 
and abdominal pain was noted in IBS-C patients. In 
Phase Ⅱb In a Ⅱb randomized double-blind placebo-
controlled multicentre study, 371 IBS-C patients were 
divided into four groups: placebo and tenapanor (5, 
20 and 50 mg) treated twice daily for 12 wk with 4 wk 
follow-up. The primary efficacy end point was met in 
60.7% of the tenapanor-treated group (at a dose of 
50 mg) vs 33.7% of the placebo-treated group. The 
overall responder was met in 50.0% of the tenapanor-
treated group (50 mg) vs 23.6% for placebo (after 12 
wk). After 12 wk, adequate relief in IBS-C symptoms 
was observed in 63.1% of the tenapanor-treated 
group (50 mg twice daily) vs 39.3% in placebo. The 
effectiveness of tenapanor therapy was maintained 
during entire time of the clinical study. The treatment 
satisfaction patient scale questionnaire showed that 
tenapanor-treated (50 mg) IBS-C patients were 
quite or very satisfied (65% vs 38% for the placebo-
treated group). The drug was well tolerated in all 
groups, and no serious adverse effects were noted. 
The most common adverse effect was diarrhoea in 
the tenapanor-treated group (50 mg twice daily), 
reported in 11.2% of IBS-C patients vs 0% in placebo. 
Safety and tolerability In the preclinical studies in rats, 
tenapanor did not influence gastric emptying[187].
Piromelatine
Melatonin is engaged in the regulation of gastro-
intestinal motility and sensation. When administered 
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orally in pharmacological doses, it has shown beneficial 
effects on abdominal pain in IBS patients without any 
effects on sleep disturbances[188]. It was also shown 
that oral melatonin significantly stimulated colonic 
transit time in healthy subjects, and it may be a 
promising option for future research on the agents 
modulating bowel motility[189]. Melatonin synthesized 
in the enteroendocrine cells of the intestinal mucosa 
reaches the liver via the portal vein[190]. Melatonin is a 
potent accelerator of duodenal mucosal bicarbonate 
secretion, which neutralizes the acid content of the 
stomach in the duodenum, and it seems to be engaged 
in the acid-induced stimulation of the secretion[191]. 
Melatonin protects the gastrointestinal mucosa due 
to an antioxidant action, a decrease in secretion of 
hydrochloric acid, stimulation of the immune system, 
promotion of epithelial regeneration, and increased 
microcirculation[192,193].
Recently, it was shown that patients with IBS had 
significantly lower 6-SMLT (6-sulphatoxymelatonin)/
creatinine level compared with healthy controls[194]. 
The lack of statistical difference in 6-SMLT/creatinine 
levels between the constipation and diarrhoea groups 
is difficult to explain. In some patients, the symptoms 
could be recurrent, or there could be some subjects 
with mixed (IBS-M) or unsubtyped (IBS-U) IBS. 
This study’s results agree with those obtained by 
Bultman[195] and Lu et al[196] who performed the study 
on female patients with IBS and found decreased 
salivary melatonin and urine 6-SMLT level compared 
to non-IBS volunteers. Low melatonin levels were 
observed in women with eating disorders. Low mela-
tonin concentrations have been associated with increased 
depressive symptoms, such as sadness, bodily discomfort, 
inner tension, difficulties in attention concentration and 
pain.
Serotonin, an endogenous amine and the precursor 
of melatonin, synthesized and released from entero-
endocrine cells of the gastrointestinal mucosa is thought 
to play an important role in the pathogenesis of IBS[197]. 
Antagonists of the serotonin 5-HT3 receptor are 
beneficial in patients with IBS-D, whereas the partial 
agonist of the serotonin 5-HT4 receptor (tegaserod) 
alleviates symptoms of IBS with constipation, especially 
in females. The role of melatonin as the regulator of 
circadian and seasonal rhythmicity has been estab-
lished[198,199]. Patients with functional disorders of 
the gastrointestinal tract also had sleep disorders, 
and some of them suffered from increased neural 
excitability and anxiety[199,200]. There were speculations 
concerning a possible role of melatonin in functional 
dyspepsia (FD), particularly ulcer-like dyspepsia. In 
two types of FD, one with epigastric pain and another 
with postprandial distress syndrome, the melatonin 
level is varied, and different dyspeptic symptoms may 
be related to differences in melatonin secretion. Sleep 
disturbances are common in patients with IBS and are 
among the most important extraintestinal symptoms, 
markedly affecting quality of life and psychosocial 
well-being[201]. In a double-blind placebo-controlled 
study, Camilleri et al[202] showed that melatonin 
improves abdominal pain in IBS patients with sleep 
disturbances. Currently, conventional treatment for 
irritable bowel syndrome is quite unsatisfactory. 
Despite multiple therapeutic interventions, no long-
term effect has been achieved. On the other hand, up 
to 80% of patients with IBS treated with hypnotherapy 
showed an improvement of their symptoms[203]. These 
observations emphasize the possible role of melatonin 
in the pathogenesis of irritable bowel syndrome and in 
its therapy[204,205].
Daikenchuto
Daikenchuto (TU-100), a traditional Japanese drug 
(Kampo medicine), is indicated in the treatment 
of adhesive bowel obstruction[206,207]. TU-100 is 
a mixture of extract powders from dried Japanese 
pepper, processed ginger, ginseng radix, and maltose 
powder. In many trials, the TU-100 prokinetic effect 
has been demonstrated to be useful in treating GI 
hypomotility[208]. Studies conducted on postoperative 
patients after gastrointestinal surgery showed that 
TU-100 prevented postoperative ileus, but little is 
known about the TU-100 effects in patients who did 
not undergo major gastrointestinal surgery[209]. Iturrino 
et al[210] performed a randomized controlled trial to 
evaluate the effects of oral TU-100, 2.5 g t.d.s. or 5 g 
t.d.s. compared to placebo t.d.s. on gastrointestinal 
and colonic transit, rectal compliance and sensation 
thresholds, anal sphincter pressures and bowel function 
in women with functional constipation. In this study, 
there were no significant effects on gastrointestinal 
and colonic transit, rectal compliance, anal sphincter 
pressures, recto-anal pressure difference, or rectal 
sensation thresholds. The highest dose was associated 
with lower rectal sensation thresholds for first sen-
sation and gas. There were no treatment effects on 
psychosensory symptoms, stool frequency, stool con-
sistency or quality of life[211].
On the other hand, Manabe et al[211] reported that 
TU-100 provided a clinically significant promotility 
effect in small bowel and ascending colon transit in 
healthy subjects. TU-100 is quite safe and well tolerated 
and is a potential treatment for IBS-C and functional 
constipation[210].
Recently, however, Acosta et al[212] did not report 
any significant effects of TU-100 on rectal sensation 
ratings, sensation thresholds, rectal fasting or post-
prandial tone, rectal compliance, bowel function, 
abdominal pain or bloating scores, or IBS quality of 
life. Further randomized controlled trials in patients 
with IBS-C or functional constipation using both clinical 
and validated biomarkers are required.
DA-6886
DA-6886, a gastrointestinal prokinetic benzamide 
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derivative, is a novel 5-HT4 receptor agonist. Ex-
perimental studies showed that it may represent a 
highly potent and selective 5-HT4 receptor agonist to 
stimulate colonic transit in mice, having a favorable 
safety profile in patients with IBS-C and chronic 
constipation[213]. Currently, a phase Ⅰ dose block-
randomized double-blind placebo-controlled single/
multiple dosing dose escalation clinical trial with an 
open-labelled food effect is being conducted to evaluate 
the safety and pharmacokinetics of single-dose 
DA-6866 in healthy male subjects[214].
Table 3 sums up the literature findings about irritable 
bowel syndrome-C therapies.
THERAPEUTIC TARGET IN DIARRHOEA-
PREDOMINANT IRRITABLE BOWEL 
SYNDROME
To date, the treatment options for IBS-D are limited 
and frequently unsuccessful. However, the incidence 
of IBS-D is currently increasing, thus causing a 
heavy economic burden both for patients and health 
care systems worldwide. As for IBS-C, a complete 
understanding of IBS-C pathophysiology has favoured 
the use of sensory end points such as complete 
spontaneous bowel movements and the FDA combined 
end point (abdominal pain and complete spontaneous 
bowel movements) in clinical trials[79].
Furthermore, also in the setting of IBS-D, pre-
clinical studies in rodents have recently improved 
the understanding of the mechanisms underlying the 
alterations in gastrointestinal motility, sensitivity and 
secretion. A number of drugs that we will touch upon 
in the next section are actually in development.
Ramosetron
Ramosetron is a potent and selective 5-HT3 receptor 
antagonist. 5-HT3 receptors can be widely found 
in the central and peripheral nervous system[215]. 
Intraluminal stimuli favour the release of 5-HT from 
enterochromaffin cells located in the mucosa[215]. When 
secreted, 5-HT can activate 5-HT3 receptors located 
on intrinsic primary afferent neurons with submucosal 
terminals. Thus, the peristaltic reflex and intestinal 
secretion can occur[215,216]. 5-HT also activates 5-HT3 
and 5-HT4 receptors located on primary afferent 
neurons of both splanchnic and vagal fibres, which are 
involved in sensory and motor responses[217].
In experimental studies, corticotrophin-releasing 
hormone (CRH) exogenously administered or released 
from the central nervous system by stress peripherally 
activates the release of 5-HT, which in turn promotes 
defecation through the 5-HT3 receptor. Ramosetron 
decreased defecation by CRH in a dose-dependent 
way[218-219].
The first 5-HT3 receptor antagonist to be introduced 
was Alosetron, which has been demonstrated to be 
effective in the treatment of female patients with 
IBS-D[220]. However, due to serious gastrointestinal 
events (ischemic colitis and severe constipation), 
it is still only available in the United States and is 
indicated for women with severe D-IBS refractory to 
conventional therapy.
Ramosetron was first tested by Lee et al[221] in a 
multicentre randomized open-label trial on 343 men 
with IBS-D. Patients were randomized to a 4-wk 
treatment of ramosetron 5 mg once daily or mebeverine 
135 mg three times daily. An improvement in abdominal 
pain/discomfort and bowel habits in the ramosetron and 
mebeverine groups was observed during the treatment 
period. A significant reduction in abdominal pain/
discomfort and urgency, stool form score, and stool 
frequency severity scores in both treatment arms was 
reported compared with the baseline.
Adverse events were observed in 7% and 4% of 
patients treated with ramosetron and mebeverine, 
respectively, even though no statistical significant 
differences were reported. Additionally, all the side 
effects were mild or moderate[221].
Successively, Fukudo et al[222] performed a ran-
domized double-blind placebo-controlled trial to 
determine whether ramosetron reduces diarrhoea 
in 296 male outpatients with IBS-D. Patients were 
treated with 5 mg of oral ramosetron (n = 147) or 
placebo (n = 149) once daily for 12 wk after a 1-wk 
baseline period. The primary end point was increased 
stool consistency in the first month. Secondary end 
points were the relief of overall IBS symptoms and 
the improvement of IBS-related quality of life. In the 
first month, patients on ramosetron treatment (74, 
50.3%) showed an improvement of stool consistency 
compared to placebo (29, 19.6%) (P < 0.001). In 
patients treated with ramosetron, the monthly relief 
of overall IBS symptoms and IBS-related quality of 
life was demonstrated compared with placebo. Safety 
was evaluated in all 296 patients, with side effects 
occurring in 46.9% and 51.7% of ramosetron and 
placebo patients, respectively. All constipation and hard 
stools experienced in the ramosetron group that were 
related to the pharmacologic actions of ramosetron 
were classified as mild and resolved early without using 
rescue drugs[222].
In another randomized double-blind placebo-
controlled trial performed by Fukudo et al[223] on 576 
female outpatients with IBS-D, patients were given 
either 2.5 μg ramosetron or placebo once daily for 
12 wk. Patients treated with ramosetron reported 
global improvement, increased stool consistency, a 
significant decrease in abdominal pain and discomfort 
and significant improvement in QOL compared with 
placebo. Of the patients tested with ramosetron, 
11.0% complained of constipation[223]. Successively, in 
a phase Ⅲ open-label uncontrolled long-term safety 
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Drug Ref. No. of patients Study design Outcome
Linaclotide Andresen 
et al[82]
36 women with 
IBS-C
Phase Ⅱa randomized, double-blind, placebo- 
controlled trial. Patients were randomized in a 
1:1:1 fashion to placebo, linaclotide 100 μg, and 
linaclotide 1000 μg and was evaluated the effect 
of 5 d
No treatment effects were seen for gastric emptying or 
colonic filling with linaclotide. Significant treatment 
effects were found for ascending colon emptying t
½ times (P = 0.015) and overall total colonic transit 
times at 48 h (P = 0.02), for the 1000 μg dose (P = 0.004) 
but not the 100 μg dose, as well as overall treatment 
effects on increased stool frequency, decreased 
stool consistency, improved ease of passage, and 
acceleration of time to first bowel movement (P < 
0.001)[82]
Johnston 
et al[83]
420 patients 
with IBS-C
Phase Ⅱb randomized, double-blind, parallel-
group, multicenter, placebo-controlled trial 
evaluate 12 wk of linaclotide at a daily dose 
range of 75-600 μg
Compared with placebo, all doses of linaclotide 
significantly improved bowel habits, including 
frequency of SBMs and CSBMs, severity of straining, 
stool consistency, as well as abdominal pain scores. 
Abdominal discomfort, bloating, and global IBS-C 
measures were also improved, for all doses except 
for the 75 μg (abdominal discomfort) and 150 μg dose 
(bloating). Effects were present for the first week, and 
sustained throughout the 12 wk of treatment
Chey et al[84] 804 adults with 
IBS-C
Phase Ⅲ trials randomized, double-blind, 
placebo-controlled to receive linaclotide 290 lg 
or placebo daily for 26 wk, with change-from-
baseline end points measuredat 12 and 26 wk
Over 12 wk, the FDA combined primary end 
point was achieved by 33.7% of patients receiving 
linaclotide compared with 13.9% of patients receiving 
placebo (P < 0.0001)
Videlock 
et al[109]
7 trials of 
linaclotide in 
patients with 
IBS-C or CC
A meta-analysis from MEDLINE, EMBASE, 
and the Cochrane central register of controlled 
trials were searched for randomized, placebo-
controlled trials
The NNT for the primary endpoint of these trials (3 
SCBMs/wk and an increase of C1 SCBM/wk, for 75% 
of weeks) was 7 (95%CI: 5-8)
Rao 
et al[86]
803 adults with 
IBS-C
Phase Ⅲ trials randomized, double-blind, 
placebo-controlled to receive linaclotide 290 lg 
or placebo once/d for 12 wk
Linaclotide demonstrated statistically significant 
improvements in all primary and secondary efficacy 
end points compared with placebo Severity of 
straining, constipation, and stool consistency also 
improved in the linaclotide group compared with the 
placebo group
Plecanatide Miner et al[92] 951 patients 
with CIC 
Phase Ⅲ, randomized, double-blind trial, 
received plecanatide 0.3, 1 or 3 mg, or placebo 
once/d for 12 wk 
The proportion of overall responders was significantly 
greater with plecanatide 3 mg compared with placebo 
(19% vs 10.7%, P = 0.009); weekly responder rates 
were also significantly greater for plecanatide 3 mg 
than placebo for weeks 1-12. Improvements in stool 
frequency, consistency, straining, and quality of life 
were also noted with the 3-mg dose vs placebo. Data 
for other plecanatide doses were not reported
Prucalopride Quigley 
et al[88]
620 patients 
with CC
A double-blind, placebo-controlled study. 
Patients receiving 2 or 4 mg of prucalopride for 
12 wk 
Increased one or more CSBMs per week compared to 
patients in the control group
Camilleri 
et al[98]
713 patients 
with CC
A double-blind, placebo-controlled study. 
Patients receiving 2 or 4 mg of prucalopride for 
12 wk
Increased frequency of three or more CSBMs per 
week, and improved evacuation completeness, 
perceived disease severity, and quality of life
Müller-
Lissner 
et al[97]
Elderly patients 
aged 65 years 
and older with 
CC
A double-blind, placebo-controlled study No changes in electrocardiogram or corrected QT 
(QTc) interval were reported, indicating its safety for 
the treatment of CC in the elderly
Patients receiving 2 or 4 mg of prucalopride for 
12 wk
Ke et al[102] 4 Randomized, 
Placebo-
controlled 
Studies
A Pooled Analysis Safe and well-tolerated It was also effective in 
improving the abdominal symptoms of CC such 
as abdominal discomfort, bloating, straining, and 
painful bowel movements 
YKP10811 Shin et al[114] 55 patients A single-center, randomized, parallel-group, 
double-blinded, placebo-controlled study were 
assigned randomly to groups given YKP10811 
10 mg (n = 15), 20 mg (n = 16), 30 mg (n = 15), or 
placebo (n = 11) daily for 8 d
Enhanced gastrointestinal and colonic transit and 
improved bowel function during an 8-d treatment 
trial. In general, the 10-mg and 20-mg doses were 
the most effective in accelerating colonic transit. No 
serious adverse events were observed
Renzapride Camilleri 
et al[101]
46 women with 
IBS-C
In a phase Ⅱ study Renzapride 4 mg q.d. accelerated colonic transit and 
increased ascending colon emptying vs placebo
George 
et al[130]
510 patients Multicentre, randomized, placebo-controlled, 
double-blind study men and women were 
randomized to placebo or renzapride (1, 2 or 4 
mg/d) for 12 wk
4 mg renzapride q.d. in terms of improving frequency 
of bowel movements and stool consistency
Table 3  Summary of the literature findings about irritable bowel syndrome-C therapies
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Ford et al[131] 29 RCTs were 
eligible for 
inclusion
Meta-analysis of placebo-controlled clinical Renzapride and cisapride were not more effective 
than placebo in IBS patients
Mozaffari 
et al[133]
2528 C-IBS and 
non C-, non 
D-IBS patients 
Meta-analysis from randomized placebo-
controlled clinical trials
Renzapride has no significant advantage over placebo 
in relieving symptoms in IBS patients
Velusetrag Manini 
et al[115]
60 healthy 
volunteers
Phase Ⅱ clinical trials, pt were randomly 
assigned, in double-blind fashion, to placebo, 
5, 15, 30 or 50 mg velusetrag, with transit 
measurements after single and 6-d dosing
Single doses of velusetrag (30 and 50 mg), but not 
placebo, accelerated colonic transit, as measured by 
colonic filling at 6 h and geometric center at 24 h 
Goldberg 
et al[140]
401 subjects 
with CC
In a Phase Ⅱ randomized, double-blind, 
placebo-controlled trial
Short bowel movement (SBM) frequency, complete 
SBM and other associated symptoms with CC were 
significantly improved in comparison with placebo in 
patients who received velusetrag for 4 wk
Naronapride Dennis 
et al[149]
 210 patients 
with CC.
Phase Ⅱ, randomized, double-blind, placebo-
controlled, dose definition study (orally 20, 
40, 80 and 120 mg twice a day) to evaluate the 
clinical effects of 9 days’
There were borderline effects on gastric emptying 
at half-time; however, ATI-7505 accelerated colonic 
transit at 24 h and ascending colonic emptying
Chenodeoxycolic 
acid
Odunsi-
Shiyanbade 
et al[155]
60 healthy 
volunteers
Randomized controlled trial, CDCA 500 mg and 
1000 mg given for 4 d 
Significant increases in stool frequency, decreases in 
stool consistency, and improvements in ease of stool 
passage were reported with CDCA
Rao et al[153] 36 female 
patients
Double-blind placebo-controlled study Accelerated colonic transit and improved bowel 
function
Elobixibat Simrén 
et al[162]
30 patients Dose-finding randomized trial five dose-levels 
(range: 0.1-10 mg/d) or to placebo
Increased C4, reduced LDL cholesterol and increased 
colonic transit from 3 to 1.9 d, and increased the 
number of SBM and CSBM/W in patients with CIC
Chey et al[157] 190 patients Were randomized to 5, 10, or 15 mg A3309 
or placebo once daily. 8-wk, multicenter, 
randomized, double-blind, placebo-controlled, 
parallel group, phase Ⅱb study,
A3309 increased stool frequency and improved 
constipation-related symptoms in CIC; effects were 
maintained over 8 wk of treatment
Lubiprostone Drossman 
et al[173]
1171 patients in 
total
Two double-blind, randomized, multicenter, 
placebo-controlled phase Ⅲ clinical trials,, 
a 12-wk randomized 2:1 to receive either 
lubiprostone 8 lg or matching placebo twice/d 
with food; a 36-wk open-label extension study
Lubiprostone was superior to placebo in the 
primary end point of overall responders, greater 
improvements in all secondary outcome measures 
compared with placebo
Chey et al[174]
Johanson 
et al[175]
479 patients in 
total
Two 4-wk phase Ⅲ, randomized, double-blind, 
placebo-controlled, multicenter clinical trials
Patients treated with lubiprostone had a statistical 
higher frequency of SBMs during the first week of 
treatment compared with placeboBarish et al[82]
Hyman 
et al[176]
127 pediatric 
patients with 
CIC (mean age 
10.2 yr) 
An open-label 4-wk clinical trial Demonstrated that lubiprostone was efficacious and 
well tolerated at total daily doses of 12-48 lg
AZD1722 Rosenbaum 
et al[185]
181 patients 
with IBS-C
Phase Ⅱa In a Ⅱa double-blind, randomized 
placebo-controlled study, Tenapanor was given 
orally at the doses of 10, 30 and 100 mg once 
daily for 4 consecutive weeks with 2 wk follow-up
The primary end point [change in complete 
spontaneous bowel movements (CSBM) from 
baseline to week 4] was not met in this study and the 
incidence of diarrhea was comparable with placebo 
group. However, improvement in bloating and 
abdominal pain was noted in IBS-C patients
Rosenbaum 
et al[186]
371 IBS-C 
patients
Phase Ⅱb In a Ⅱb randomized, double-blind, 
placebo-controlled, multicenter study
The overall responder was met in 50.0% of tenapanor-
treated group (50 mg) vs 23.6% for placebo (after 12 
wk). After 12 wk, adequate relief in IBS-C symptoms 
was observed in 63.1% of tenapanor-treated group (50 
mg twice daily) vs 39.3% in placebo
Rosenbaum 
et al[187]
356 patients A double-blind, placebocontrolled, randomized 
phase 2b trial 12-wk dose-ranging study 
evaluating tenapanor 5 mg, 20 mg or 50 mg b.i.d. 
vs placebo (1/2)
Tenapanor 50 mg b.i.d. significantly improved 
CSBM responder rate (primary endpoint) compared 
with placebo in patients with IBS-C. Tenapanor 50 
mg b.i.d. also improved key secondary endpoints 
compared with placebo, including overall responder 
rate, abdominal pain responder rate and stool 
frequency. In addition, improvements were observed 
in several exploratory endpoints addressing a range 
of symptoms in patients with IBS-C. Tenapanor was 
generally well tolerated and had minimal systemic 
availability. Tenapanor shows promise as a future 
treatment option for patients with IBS-C
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trial, the long-term safety and efficacy of 2.5 and 5 μg 
of ramosetron treatment in women with IBS-D was 
reported. However, the authors of the study concluded 
that “clinicians should be aware that one-fifth of 
women with IBS-D receiving ramosetron may suffer 
from constipation during treatment”[224].
Finally, a recent systematic review and meta-
analysis performed to explore of the safety and efficacy 
of ramosetron both in male and female patients with 
IBS-D concluded that ramosetron is efficacious in both 
male and female patients with diarrhoea-predominant 
IBS, even if large-scale studies are needed to assess 
its effects on different ethnicities[225].
LX-1031
LX-1031 is a tryptophan hydroxylase (TPH) inhibitor 
that reduces peripheral serotonin production. It is 
indicated for conditions characterized by excess 5-HT 
expression such as IBS-D and, possibly, carcinoid 
diarrhoea. The blocking of excess 5-HT effects is well 
established[226]. Previously, pharmacological attempts 
aimed at inhibiting 5-HT synthesis, such as para-
chlorophenylalanine, but the central adverse effects 
due to the inhibition of brain 5-HT synthesis with 
consequent affective disorders blocked their use[227].
LX-1031 does not cross the blood-brain barrier and, 
thus, does not pose risk of depression[228].
In a phase Ⅱ multicentre randomized double-blind 
placebo-controlled proof-of-concept study[229] performed 
on 155 patients, the subjects were assigned randomly 
in a double-blind fashion to 1 of 2 doses of LX1031 
(250 mg 4 times/d or 1000 mg 4 times/d) or placebo 
taken daily during the 28-d treatment period[229]. 
Patients treated with LX1031 at the dose of 1000 mg 
significantly improved the primary efficacy end point, 
namely, the relief of IBS pain and discomfort, compared 
with placebo at week 1. No significant improvements 
were observed at weeks 2, 3 or 4. Adverse effects 
reported were generally mild, self-limited, and evenly 
distributed across the placebo and both LX1031 
treatment arms[229]. The relationship between clinical 
improvement and reduction in serotonin synthesis 
shown in this study supports LX1031’s proposed mecha-
nism of action in IBS and thus supports serotonin 
synthesis inhibition in the GI tract as a novel therapeutic 
strategy for the treatment of IBS-D[229].
ASP-7147
Activation of the Bombesin-2 receptor may be involved 
in the regulation of gastrointestinal motility and in-
testinal secretion. ASP7147 is a novel small molecule 
Bombesin-2 receptor antagonist that reduces motility 
and intestinal secretions. Indeed, ASP 7147-mediated 
inhibition of this receptor may improve symptoms in 
patients with IBS-D. In the RCT performed by Lembo 
et al[230] on 64 patients during a 4-wk study, ASP7147 
showed promise as a safe and effective new therapy 
for both men and women with IBS-D, demonstrating 
improvement in multiple symptoms of IBS-D. The per-
sistence of treatment effect suggests the possibility of 
retained efficacy with less-frequent dosing in follow-on 
trials[230].
JNJ-27018966
JNJ-27018966 is a dual μ-opioid agonist and δ-opioid 
receptor antagonist that has been shown to have 
benefits in patients with IBS-D[231]. A randomized 
controlled double-blind study compared JNJ-27018966, 
at doses of 25, 100 and 200 mg twice daily, to placebo 
in 807 patients with IBS-D. Diarrhoea and pain 
were significantly improved in patients treated with 
JNJ-27018966 at the doses of 25 and 200 mg twice-daily 
compared to placebo (12, 13.8 and 5.7%, respectively, 
P < 0.05 for both comparisons to placebo)[232].
ROSE-010
ROSE-010 is a glucagon-like peptide 1 analogue that 
decreases gastric emptying and motility[1]. Hellström 
et al[233] conducted a randomized crossover placebo-
controlled trial on 160 patients with IBS and associated 
abdominal pain treated with ROSE-010 100 μg once daily, 
300 μg once daily or placebo. ROSE-010 was associated 
with a twofold greater response to abdominal pain 
compared to placebo (P < 0.05 for all comparisons) and 
significantly higher patient-reported satisfaction (P < 
0.05). The most frequent treatment-related side effect 
was nausea, which was experienced by 19, 37 and 0% 
of ROSE-010 100 μg, ROSE-010 300 μg and placebo, 
respectively[233-234].
AST-120
AST-120, also known as kremezin, is an orally admini-
stered intestinal sorbent that has been reported to slow 
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Neu p11 
(piromalatine)
Camilleri 
et al[202]
40 IBS patients In double blind placebo controlled study were 
randomly assigned to receive either melatonin 
3 mg (n = 20) or matching placebo (n = 20) at 
bedtime for two weeks
Melatonin 3 mg at bedtime for two weeks 
significantly attenuated abdominal pain and reduced 
rectal pain sensitivity without improvements in sleep 
disturbance or psychological distress. The findings 
suggest that the beneficial effects of melatonin 
On abdominal pain in IBS patients with sleep 
disturbances are independent of its action on sleep 
disturbances or psychological profiles
IBS : Irritable bowel syndrome.
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dose of 1.0 mg showed borderline significant effects. 
In a clinical trial conducted on patients with IBS, the 
average pain 2 h post-on-demand treatment with 
asimadoline was not significantly decreased. At the 
post hoc analyses, asimadoline was demonstrated 
to be effective in mixed IBS[242]. Successively, in a 
randomized controlled double-blind trial conducted on 
596 patients with IBS-D, asimadoline at doses of 0.15, 
0.5 and 1 mg twice daily was compared to placebo. 
Patients treated with asimadoline at a dose of 0.5 mg 
twice daily had a twofold significant improvement in 
the total number of months with adequate relief of IBS 
pain, pain scores, urgency and frequency[243,244].
Colesevelam
Bile acids have several physiologic functions and 
are actively reabsorbed (up to 95%) in the terminal 
ileum[245,246]. Disruption of the enterohepatic circulation 
of bile acids due to ileal disease (inflammatory bowel 
diseases) or idiopathic bile acid malabsorption is 
responsible for chronic diarrhoea[246]. Faecal con-
centrations of bile acids in IBS-D or functional diarrhoea 
are unknown. While earlier studies suggested up-
regulation of the ileal active transporter[247] as a result 
of chronic loss of bile acids (which may reduce the bile 
acids reaching the colon), other data suggest increased 
delivery to the colon may occur if the ileal reabsorptive 
capacity for bile acids is exceeded[246].
Odunsi-Shiyanbade et al[155] showed in 12 IBS-D 
patients that colesevelam modestly affected overall 
colonic transit (in patients treated with colesevelam, the 
emptying of the ascending colon was approximately 4 h 
longer compared to placebo). Furthermore, colesevelam 
favoured stool passage and somewhat firmer stool 
consistency. No effects on mucosal permeability or 
safety were found[246]. Successively, Camilleri et al[248] 
performed a 10-d single-center unblinded single-dose 
trial on the effects of colesevelam in 12 IBS-D patients. 
They demonstrated that colesevelam accelerates 
the delivery of BAs to stool, while improving stool 
consistency. It also stimulates hepatic BA synthesis, 
avoiding steatorrhea in patients with IBS-D. The 
overall effects are due to luminal BA sequestration 
by colesevelam[248]. All the abovementioned studies 
suggest that there is an opportunity to diagnose and 
specifically treat the cause of symptoms in IBS-D.
Solifenacin
Solifenacin is a muscarinic type 3 receptor antagonist 
recommended in the treatment of overactive bladder 
(OAB) in adults[249]. Since 1967, M3 receptor antagonists 
such as mepenzolate bromide have been used in 
Japan as modulating agents of gastrointestinal motility. 
However, no clinical trials had been designed to evaluate 
the efficacy for IBS defined under the modern Rome 
criteria. Given the high rate of comorbidity between IBS 
chronic kidney disease (CKD) progression and to delay 
the initiation of dialysis by reducing the levels of renal 
toxins or their precursors in the gastrointestinal (GI) 
tract[235,236].
It has been shown that AST 120 exerts its properties 
in IBS by acting on intestinal permeability, reduction of 
visceral sensitivity and alteration of gut motility[236]. In 
a randomized double-blind controlled study conducted 
on 115 non-constipation-related IBS patients, AST-120 
at a dose of 2 g three times daily significantly improved 
the percentage of patients with at least a 50% decrease 
in the number of days with abdominal pain compared to 
placebo (26.8% vs 10.2%, respectively). Additionally, 
AST-120 significantly improved bloating and stool 
consistency compared to placebo. The safety profile of 
AST-120 was similar to that of placebo[237].
Ibodutant
Antagonists of NK2 receptors have been suggested 
to modulate gastrointestinal chemical-induced im-
paired motility and stress-induced impaired bowel 
habits in humans, as recent phase 2 clinical trials have 
reported[238]. In a randomized double-blind controlled 
trial conducted on 559 IBS-D patients, ibodutant, a 
neurokinin-2 receptor antagonist, significantly improved 
abdominal pain, overall symptoms and quality of life 
compared to placebo. Ibodutant at doses of 1, 3 or 10 
mg once daily showed superiority over placebo, with 
the 10 mg once daily dose being the most effective and 
women showing a better response than men[239,240]. 
Considering the limited number of effective available 
therapeutic options for IBS-D, ibodutant may become 
an important and safe treatment option, depending 
on whether ongoing phase 3 studies will confirm the 
efficacy observed in phase 2 studies[238].
Asimadoline
Asimadoline, a kappa-opioid receptor agonist, acts 
peripherally, inducing analgesic and antidiarrheal 
effects[241]. Action in the central nervous system is not 
required for asimadoline efficacy in the treatment of IBS. 
Asimadoline reduces sensation in response to colonic 
distension at subnoxious pressures in healthy subjects 
and in IBS patients without impairment of colonic 
compliance. Asimadoline decreased the appetite and 
enhanced the postprandial gastric volume (in healthy 
women). However, there were no significant effects on 
gastrointestinal transit, colonic compliance, fasting or 
postprandial colonic tone. In a clinical trial conducted 
on 40 patients with functional dyspepsia (according 
to Rome Ⅱ criteria), asimadoline did not significantly 
impair appetite or symptoms over 8 wk. However, 
asimadoline at a dose of 0.5 mg significantly reduced 
the appetite in patients, with higher postprandial 
fullness scores and daily postprandial fullness severity 
(over 8 wk). Patients treated with asimadoline at a 
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and OAB[250], and considering that solifenacin acts on 
bowel dysfunction similarly to darifenacin, a selective 
M3 receptor antagonist with equivalent potencies, 
solifenacin was evaluated on symptomatic relief in 20 
IBS-D patients in an open-label trial[249]. After a 2-wk 
observation period, solifenacin was administered for 6 
wk. Later, solifenacin was suspended, and ramosetron, 
a serotonin 3 receptor antagonist, was given for 4 wk. 
Solifenacin was not inferior to ramosetron in the treat-
ment of IBS with diarrhoea[249].
The results of this study suggested the potential 
therapeutic application of solifenacin in the treatment 
of IBS-D. However, the possible placebo effect could 
not be excluded. Therefore, further placebo-controlled 
parallel group studies are required to confirm the 
efficacy of solifenacin[249].
Tiropramide
Tiropramide, a derivative of tyrosine, has a spasmolytic 
effect on the intestine, decreasing Ca2+ release into 
intestinal smooth muscle[251-253]. In a double-blind 
placebo-controlled randomized trial performed by 
Lee et al[251], tiropamide was associated with an 
improvement of total symptom scores for 4 wk com-
pared with 3 wk in the placebo group. In addition, only 
patients treated with tiropramide improved abdominal 
pain at week 4[254].
Lee et al[251] successively performed a multicentre, 
randomized, non-inferiority trial involving 287 patients 
with IBS randomly assigned to either tiropramide 
100 mg or octylonium 20 mg t.i.d. (means 3 times 
a day) for 4 wk[1]. The visual analogue scale (VAS) 
scores of abdominal pain at week 4 were significantly 
reduced in both tiropramide and octylonium groups, 
even though the change from baseline was similar in 
the 2 groups[251]. In both groups, abdominal pain and 
discomfort assessed using VAS scores, diaries and IBS-
QoL were improved, and no differences in the changes 
from baseline were observed. Side effects were similar 
in both groups. No severe side effects involving either 
drug were observed[251].
Despite the useful results of the abovementioned 
study, further studies are required to elucidate tiro-
pramide’s pharmacodynamic and pharmacokinetic pro-
perties and its mechanism of action on the intestine[251].
Eluxadoline
Eluxadoline is a μ- and κ-opioid receptor agonist and 
δ-opioid receptor antagonist. Its action is directed to 
the enteric nervous system, with slight side effects in 
the central nervous system. Its use was approved by 
the United States Food and Drug Administration on 
May 2015[255-257].
Patients with IBS-D receiving eluxadoline (100 
mg twice daily) in a phase Ⅱ dose-ranging study had 
greater efficacy compared with patients receiving 
placebo after 12 wk[258]. Eluxadoline improved the 
number of daily bowel movements and decreased the 
episodes of urgency and incontinence experienced 
by patients during the 3-mo treatment period[258]. 
Eluxadoline had an overall favorable safety profile, with 
nausea, abdominal pain, vomiting, and constipation 
the most commonly reported AEs[258].
Subsequently, in two large Phase 3 trials (IBS-3001 
and IBS-3002), the efficacy of eluxadoline in patients 
with IBS-D was shown[259].
Finally, Cash et al[260] reported pooled safety and 
tolerability data from Phase 2 and 3 clinical studies 
for the approved doses of eluxadoline: 75 and 100 
mg. The authors demonstrated that constipation and 
nausea were the most common adverse events[260]. 
Consistent with the known adverse effects of opioid 
agonists, clinically apparent sphincter of Oddi spasm 
events were observed in eluxadoline-treated patients 
without a gallbladder. The majority of these cases were 
observed in patients on the higher dose of eluxadoline, 
thus suggesting a possible association[260].
Table 4 sums up the literature findings about irritable 
bowel syndrome-D therapies.
CONCLUSION
IBS currently remains a field of intense therapeutic 
research, in which most of the aforementioned studies 
focus on stool-pattern-specific subcategories of patients 
with this condition. Multiple further drugs are also under 
evaluation. Among these, alpha galactosidase (AG) was 
shown to reduce meteorism associated with black bean 
ingestion, even though it is unknown whether it may 
have a benefit on IBS[261]. However, in a subsequent 
study performed by Hillilä et al[262], no evidence to 
support the use of AG routinely in IBS patients was 
found.
With regards to therapies restoring intestinal 
permeability, multiple studies with prebiotics and 
probiotics[263] are ongoing, even if to date their efficacy 
has been limited. In parallel, much progress has been 
made in targeting low-grade inflammation, especially 
through the introduction of drugs such as mesalazine 
and rifaximin, even if a better knowledge of the mecha-
nisms underlying the low-grade inflammation in IBS 
may support the design of clinical trials aimed at 
evaluating the efficacy and safety of such drugs.
On the other hand, the non-pharmacological treat-
ment of IBS is often viewed as attractive. Faecal 
microbiota transfer, dietary interventions, holistic and 
integrative medicine approaches currently represent 
possible future therapeutic alternatives in this setting.
In conclusion, long-term studies and comparative 
studies with pharmacotherapy, as well as elucida-
tion of the underlying mechanisms of action, are still 
needed to find the correct algorithm to manage IBS 
patients.
Sinagra E et al . New therapeutic perspectives in IBS
6618 September 28, 2017|Volume 23|Issue 36|WJG|www.wjgnet.com
Drug Ref. No. of pt Study design Outcomes
Ramosetron Lee et al[213] 343 male pt A multicenter, randomized, open-label trial 
male patients with IBS-D; pt were randomized 
to either a 4-wk treatment of ramosetron 5 mg 
once daily ,or a 4-wk treatment of mebeverine 
135 mg three times daily
Global IBS symptoms, abdominal pain/discomfort 
and abnormal bowel habits in the ramosetron 
and mebeverine groups significantly increased 
during the treatment period. The severity scores 
of abdominal pain/discomfort and urgency, 
the stool form score, and the stool frequency in 
both treatment arms were significantly reduced, 
compared with the baselines
Fukudo et al[222] 296 male pt A randomized, double-blind, placebo-
controlled trial in male patients with IBS-D 
Patients were given 5 mg oral ramosetron (n = 
147) or placebo (n = 149) once daily for 12 wk 
after a 1-wk baseline period
Improving stool consistency in the first month. 
The ramosetron group had significantly higher 
monthly rates of relief of overall IBS symptoms 
and IBS-related quality of life than the placebo 
group. Adverse events occurring in 46.9% and 
51.7% of ramosetron and placebo patients, 
respectively
Fukudo et al[223] 576 female pt A randomized, double-blind, placebo-
controlled trial. The subjects received either 2.5 
μg ramosetron or placebo once daily for 12 wk.
Global improvement, an increased stool 
consistency a significant reductions in abdominal 
pain and discomfort and greater improvement in 
QOL compared with placebo
Lx1031 Brown et al[229] 155 patients A phase-Ⅱ multicenter, randomized, double-
blind, placebo-controlled, the subjects were 
assigned randomly in a double-blind fashion 
to 1 of 2 doses of LX1031 (250 mg 4 times/d 
or 1000 mg 4 times/d) or placebo, taken daily 
during the 28-d treatment period
Improved significantly in patients given 
1000 mg LX1031 compared with those given 
placebo, at week 1, together with nonsignificant 
improvements at weeks 2, 3 and 4. Adverse Effects 
reported were generally mild, self-limited, and 
evenly distributed across the placebo and both 
LX1031 treatment arms
ASP-7147 Lembo et al[230] 64 patients RCT performed on during a 4-wk  Demonstrating improvement in multiple 
symptoms of IBS-D. The persistence of treatment 
effect suggests the possibility of retained efficacy 
with less frequent dosing in follow-on trials 
JNJ-27018966 [232] 807 patients A randomized, controlled, double-blind study, 
25, 100, and 200 mg twice daily to placebo
The composite of diarrhea and pain was 
significantly improved in the JNJ-27018966 25 and 
200 mg twice-daily groups compared to placebo 
ROSE-010 Hellström et al[233]
160 patients
A randomized placebo-controlled trial. 
Patients were randomized to ROSE-010 100 μg 
once daily, 300 μg once daily or placebo
Treatment with ROSE-010 resulted in a two fold 
greater response to abdominal pain compared to 
placebo and significantly greater patient-reported 
satisfaction with ROSE-010. The most common 
treatment-related adverse effect was nausea
AST-120 Tack et al[95] 115 non-
constipation-
related IBS 
patients
A randomized, double-blind, controlled study AST-120 2 g three times daily significantly 
improved the proportion of patients with at least 
a 50% reduction in the number of days with 
abdominal pain compared to placebo. AST-120 
resulted in significantly improved bloating and 
numerically improved stool consistency compared 
to placebo. The safety profile AST-120 was similar 
to placebo
Ibodutant Trinkley et al[231] 559 IBS-D patients A randomized, double-blind, controlled trial Improved abdominal pain, satisfactory relief of 
overall symptoms, and quality of life compared 
to placebo. All three doses of ibodutant (1, 3, 10 
mg once daily) were superior to placebo, but 10 
mg once daily was most effective and females 
responded better than males
Asimadoline Trinkley et al[231]  596 IBS-D patients A randomized, controlled, double-blind trial 
compared asimadoline 0.15, 0.5 and 1 mg twice 
daily to placebo 
Asimadoline 0.5 mg twice daily significantly 
improved by two fold the total number of months 
with adequate relief of IBS pain, pain scores, 
urgency and frequency
Colesevelam Odunsi-
Shiyanbade 
et al[155]
12 IBS-D patients Single center trial Colesevelam modestly affected overall colonic 
transit (emptying of the ascending colon took an 
average 4 h longer in patients given colesevelam 
compared to placebo). Furthermore, colesevelam 
was associated with greater ease of stool passage 
and somewhat firmer stool consistency. No effects 
on mucosal permeability or safety were identified 
Camilleri et al[240] 12 IBS-D patients A 10-d single-center, unblinded, single-dose 
trial
Colesevelam increases delivery of BAs to stool 
while improving stool consistency, and increases 
hepatic BA synthesis, avoiding steatorrhea in 
patients with IBS-D
Table 4  Summary of the literature findings about irritable bowel syndrome-D therapies
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